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CHAPTER I
Review of the Literature

1.1

Protein folding
Proteins are the most abundant biological macromolecules within a cell and

carry out vital functions. The sequence of amino acids in a protein defines its
primary structure. However, the linear chain of amino acids only becomes a
functional protein when it folds into its three-dimensional form.

1.1.1 Protein sequence and protein structures
All proteins are polymers of amino acids (8). Each protein polymer – also
known as a polypeptide – consists of a sequence of 20 different L-α-amino acids,
also referred to as residues (9). To be able to perform their biological function(s),
proteins fold into one or more specific spatial conformations, driven by a number
of non-covalent interactions such as hydrogen bonding, ionic interactions, Van
der Waals forces, and hydrophobic packing (10, 11).
Proteins have four structural levels. The primary structure refers to the
amino acid sequence of the polypeptide chain, which is held together by covalent
bonds (peptide bonds). The secondary structure refers to highly regular local
sub-structures. Two main types of secondary structures are the α-helix and the
β-sheet. These secondary structures have a regular geometry, being constrained
to specific values of the dihedral angles φ and ψ on the Ramachandran plot. The
tertiary structure refers to three-dimensional structure of a single protein
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molecule. The α-helices and β-sheets are folded into a compact globular
structure driven by the non-specific hydrophobic interactions and is stable only
when the parts of a protein domain are locked into place by specific tertiary
interactions, such as salt bridges, hydrogen bonds, and the tight packing of side
chains. Quaternary structure is a larger assembly of several protein molecules
(subunits). These quaternary protein subunit assemblies are stabilized by the
same non-covalent interactions as the tertiary structure.

1.1.2 Protein folding
Protein folding occurs through an intermediate form, known as secondary
structure. The most common secondary structure elements are the rod-like αhelix and the plate-like β-pleated sheet. They are stabilized by non-covalent
interactions. Then, in turn, these secondary structural elements further interact,
fold, and coil to produce the tertiary structure that contains functional regions
(domains).
Although it is possible to deduce the primary structure of a protein from a
gene sequence, the tertiary structure or the quaternary structure of a protein
cannot be predicted just by its primary amino acid sequence. Meanwhile, inside
the cell, the folding rate is significantly high, in a second time-scale (12).
Therefore, to understand how a protein sequence folds into its functional
structure inside of the cell becomes one of the most important tasks for
biochemists.
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One of most popular models for protein folding is the hydrophobic collapse
model. This model proposes that, since the hydrophobic effect is the major
driving force for protein folding, formation of a hydrophobic residue cluster that
repels water must be the first step of folding. The polypeptide chain tends to
collapse to a compact state. Then the rate-limiting steps in folding can be the
reorganization of inter-residue interactions within a more-or-less disordered
collapsed state (13). This process involves complex kinetics. Some molecules
may form in the initial stages of folding between contacting residues, which
allows rapid formation of native structure. Others may generate folding
intermediates, which eventually will be reorganized to form the native
conformation.

1.1.3. Protein misfolding diseases
Protein folding in vivo is of remarkably high fidelity, but sometimes defects
can occur resulting in protein misfolding. In the 1990s, scientists started to
understand that protein misfolding is involved in the development of many
diseases (Table 1-1). Protein folding diseases can be divided into two groups. In
the first group, excessive quantities of misfolded proteins aggregate forming
amlyoid plaques, a hallmark of amyloidoses, such as Alzheimer’s and
Creutzfeldt–Jakob diseases (14). In the other group, genetic mutations lead to
incomplete folding of a protein, which affects its function. This might, for instance,
happen to the tumor suppressor p53, the loss of function of which results in
cancer (14).
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Table 1-1: Representative protein folding diseases (15)

Disease
Hypercholesterolaemia
Cystic fibrosis
Phenylketonuria
Huntington's disease
Marfan syndrome
Osteogenesis imperfecta
Sickle cell anaemia
α1-Antitrypsin deficiency
Scurvy
Alzheimer's disease
Parkinson's disease
Scrapie/Creutzfeld-Jakob
disease
Familial amyloidoses
Retinitis pigmentosa
Cataracts
Cancer

Protein
Low-density lipoprotein receptor
Cystic fibrosis transmembrane regulator
Phenylalanine hydroxylase
Huntingtin
Fibrillin
Procollagen
Haemoglobin
α1-Antitrypsin
Collagen
Amyloid α-peptide/tau
α-synuclein

Site of
folding
ER
ER
Cytosol
Cytosol
ER
ER
Cytosol
ER
ER
ER
Cytosol

Prion protein
Transthyretin/Lysozyme
Rhodopsin
Crystallins
p53

ER
ER
ER
Cytosol
Cytosol

The common characteristic of all amyloidoses is the collection of plaques
(amyloids) of insoluble protein in the extracellular tissue, which cannot be
degraded by proteases. Their structures are highly ordered and give them
crystal-like properties. Beta-pleated sheet of identical proteins are densely
packed and form long filaments (fibrils). About 20 different proteins can associate
with different diseases with unique features (16). The plaques can be transported
through the bloodstream to different tissues forming amyloid deposites,
systemically. However, the localized amyloids are more important for clinical
research because they mainly affect the central nervus system, causing
neurodegenerative diseases.
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The general mechanism of amyloid formation reveals that polypeptide
chains can adopt multiple conformational states and interconvert between them
on a wide range of time scales. The network of equilibria, which link several of
the most important states, is schematically illustrated in Figure 1-1. Through
partially folded intermediates, the protein can compact into a monomer or
associate to form oligomers or higher aggregates. Oligomers may be functional,
such as actin, myosin and microtubules. The majority of these proteins will be
degraded, usually under carefully controlled conditions and as a part of normal
biochemical processes, with their amino acids often being recycled. However,
partially folded or unfolded intermediates may enable aggregation (Figure1-1).
Some of these initial aggregates simply dissociate, while others may reorganize
to form stable oligomers, initiating amyloid structures (15).

Transmissible spongiform encephalopathies (TSEs), which include mad
cow disease (bovine spongiform encephalopathy, BSE) and Creutzfeld Jakob
disease (CJD) in humans, are special forms of amyloidoses in which the victim’s
brain degenerates to a structure that looks like a porous sponge. These
conditions seem to occur when normal protein particles called prions misfold.
The normal prion is also called PrPc, a component of the membrane of healthy
nerve cells. When it is properly folded, it remains soluble and degradable.
However, when it is misfolded in a particular way, it can take on an infectious,
incorrectly folded three-dimensional form (PrPsc) (17, 18). The infectious prion
can be transmitted in the diet and trigger a domino effect in healthy prion, forcing
it to adopt its incorrectly folded form.
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Figure 1-1: A schematic representation of the protein conformational states that are
in interconversion. The transition from β-structured aggregates to amyloid fibrils can
occur by addition of either monomers or protofibrils (depending on protein) to
preformed β-aggregates. Many of the various states of proteins are utilized
functionally by biology, including unfolded proteins and amyloid fibrils, but
conformational diseases will occur when such regulatory systems fail, just as
metabolic diseases occur when the regulation of chemical processes becomes
impaired (6).
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Another group of protein folding diseases is caused by lack of a correctly
folded protein. Protein p53 occupies an important position in the cancer
resistance network. Normally, the p53 system is switched off or in stand-by
mode. But when the cells become stressed or damaged, p53 is activated to
prevent genetic mutations, which can cause tumor formation marked by
uncontrolled division and proliferation of cells. Mutations of p53 gene lead to
misfolding of p53 and allow abnormal cell growth in an uncontrolled manner (19).
This type of mutation in p53 is thought to occur in 50% of all cases of cancer and
as many as 95% of all cases of lung cancer (20).

1.1.4. The endoplasmic reticulum-associated folding (ERAF) and the quality
control (QC) system inside mammalian cells
The endoplasmic reticulum (ER) is a large, membranous organelle that is
in physical contact with almost all other organelles inside the cells, including the
nucleus, Golgi and plasma membrane (21, 22). In the ER, once the primary
sequence of a nascent protein has been assembled and released from the ERassociated

ribosome

posttranslational

through

modification

the
to

Sec61
become

channel,
fully

it

has

functional.

to

undergo

The

main

posttranslational modifications are the formation of disulfide bonds, conformation
folding, and protein glycosylation. While folding or assembling, intermediates
expose their hydrophobic surfaces, unpaired cysteines or immature glycans.
Very high concentrations of chaperone proteins in the lumen of the ER, such as
oxidoreductases, interact with the intermediates and promote their folding. These
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chaperone proteins work in concert and form complexes, which efficiently
process proteins and ensure their proper folding.

1.1.4.1. ER chaperones and folding enzymes (foldases)
About 333 proteins of the ER protein folding machinery are known. These
include the lectins, N-glycan processing enzymes, protein disulfide isomerases,
prolyl cis-trans isomerases, and the molecular chaperones (23). Table 1-2 gives
a brief list of these proteins. ER-resident foldases such as lectins (calnexin and
calreticulin) and the general ER-chaperone BiP play key roles in regulating ERassociated folding (ERAF) and degradation (ERAD) of proteins and will be
discussed in detail below.
The canonical ER lectins are the type 1 membrane protein calnexin and
the closely related ER luminal protein calreticulin. They are two prominent ER
chaperones, calcium requiring and involved in processing Glc1Man9 N-glycans,
which are attached to nitrogen (N) residues on nascent proteins. The N- glycans
are generated by the action of glucosidase II on the Glc2Man9 glycan after
processing of Glc3Man9 by glucosidase I, or by UGGT1 mediated addition of
glucose moiety (Figure 1-2). They serve a wide array of functions including
stabilizing proteins against denaturation, enhancing solubility, orienting proteins
within membranes, adding structural rigidity, regulating protein turnover, and
mediating pathogen interactions (24).
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Table 1-2: Principal ER chaperones and foldases (12).
Family

Main members

Functions

HSP70

Bip/GRP78

Chaperone

HSP90

Endoplasmin/GRP94

Chaperone

HSP40

ERdj1-ERdj7

Co-chaperone

Lectin

Calnexin, Calreticulin

Glycoprotein quality control

EDEMs 1,2,3

Glycoprotein degradation

OS-9, XTPB-3

Glycoprotein degradation

UGGT

Folding sensor

ER glucosidases I, II

Trims off glucose from N-glycan

ER mannosidases

Removes terminal mannoses

Peptidyl-prolyl
isomerases

Cyclophilin B,
FKBP13/23/65

Isomerize peptide bonds

Ero1

Ero1α, Ero1β

Oxidation for disulfide bonds

Oxidoreductases

PDI, ERp72, ERp57, plus
many others

Disulfide bond formation and
isomerization

Glycan processing
enzymes

BiP is an abundant ER chaperone. BiP contains an N-terminal ATPase
domain, stimulated by ER resident J-domain co-chaperones, of which there are
seven (ERdj1-7) (25). When BiP binds to ATP, it adopts an open conformation.
ATP hydrolysis causes BiP to adopt a conformation with higher affinity for
substrate binding. The ADP-bound closed state of BiP can be re-opened, with
the help of the nucleotide exchange factors GRP170 and Sil1. BiP is usually the
first chaperone to bind the nascent chain to facilitate translocation of the nascent
chain into the ER lumen (Figure 1-2). ERdj1 and 2 regulate the nascent chain
binding. BiP is also found in a multi-protein complex that includes several protein
disulfide isomerases and peptidyl-prolyl cis-trans isomerases such as protein
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disulfide isomerase (PDI) and peptidyl-prolyl cis-trans isomerases (PPIs),
respectively (26). The association of chaperones with foldases in protein
complexes was proposed to direct their activities towards the nascent
polypeptide chain (27).
PDI is the primary oxidant of cysteine thiols in the ER, and one of the most
abundant ER proteins. The expression of PDI is rapidly induced under different
ER stresses (28), indicating a crucial role for PDI in protein folding quality control.
Under different microenvironments of reduction potential, it can make (oxidize),
break (reduce), and re-arrange (isomerize) disulfide bonds.
PPIs, also called rotamases, catalyze the slow isomerization of Xaaproline peptide bonds that are found in both cis and trans in folded protein.
Proline isomerization has been identified as a rate-limiting step (29). Correction
of Xaa-proline bond orientation happens when a protein has reached an almost
completely folded conformation (30, 31).

1.1.4.2. The ER folding machinery
Proteins destined for the secretary pathway and eventually the plasma
membrane, have an extra intrinsic signal sequence on the N-terminus that is
exposed as the protein begins to emerge from the ribosome. The signal
sequence is first recognized and bound to a signal recognition particle (SRP),
such as SRP54. SRP binds to translating ribosome and the emerging signal
sequence with high affinity (32). Once the SRP binds to the ribosome and
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recognizes the signal sequence, the complex is then transported to the ER
membrane where it binds to the SRP receptor (SR) (33). The SRP/SR complex
positions the ribosome over a translocon and the protein being translated enters
the lumen of the ER as it is being translated (32, 33). The translocon is a
complex that is composed of the microtubule tethering protein Climp63, the
oligosaccharyltransferase complex (OST), and glucosidase I (GlucI) (34).
Upon entering the ER lumen, proteins without N-X-S/T consensus, the Nglycosylation site, directly undergo the folding process facilitated by BiP, PDI,
and PPI. However, most secreted proteins are first tagged with N-glycan
(Glc3Man9GlcNAc2) at N-X-S/T consensus. It has been proposed that the
glycosyl moieties act as a sophisticated quality control tag for protein folding
inside the ER. The enzymes glucosidases I and II cleave terminal glucose (Glc)
residues from newly synthesized N-Glycan. The Glc1Man9 N-glycans are
recognized by the chaperones calnexin and calreticulin. Calnexin and calreticulin
with the bound protein disulfide isomerases ERp57 establishes a calnexin cycle
to accelerate the folding of Glc1Man9 N-glycan protein (35). When the glucose
residue is cleaved, calnexin and calreticulin are released from the protein. If the
protein is folded into its proper conformation upon release of the lectins, it is
sorted into COPII vesicles by cargo recruiting lectins ERGIC53, VIP36, and VIPL
that reside in the ER to Golgi intermediate compartment, called ERGIC (Figure 12).
Additional candidate protein has been proposed for cargo sorting. One
such candidate is the p24 family of type I ER membrane proteins that is highly
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conserved in eukaryotes (36). They are abundant constituents of the ER and
COPII vesicles and their C-termini binds to COPII coat proteins (SEC23).

1.1.4.3. ER quality control system
The integrated process of protein folding and targeted protein degradation
are known as the ER quality control (QC) system (37). In this system, all proteins
are subjected to a “primary” quality control check that monitors their
conformation. A secondary quality control mechanism relies on the intrinsic
signal of proteins and facilitates their transport, such as the process to send
misfolded proteins for ER-associated degradation (ERAD). The unfolded proteins
are retained in the ER. In order to promote a renewed cycle of folding, unfolded
glycoprotein can be recognized by UDP-glucose:glycoprotein-glucosyltransferase
(UGGT1) in the calnexin cycle. UGGT1 adds one glucose moiety from UDPglucose to the unfolded proteins, which bear high content of mannose (Man9) in
their N-glycans. By rebinding with calnexin and calreticulin, the misfolded
proteins re-enter the calnexin cycle and undergo further folding catalyzed by
ERp57 (38) (Figure 1-2).
Despite the presence of chaperones, some proteins persistently fail to be
folded and processed properly, which can lead to the formation of nonfunctioning protein aggregates. A 1, 2-mannosidase I will cleave a mannose
residue (Man) from the oligosaccharides of these proteins (39). This leads to the
recognition by the ER degradation-enhancing 1, 2-mannosidases-like protein
(EDEM). Then the glycoproteins are targeted for degradation by ER-associated
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degradation (ERAD) or the ubiquitin- proteasome system through the disposal
pathway (40) (37).

1.1.4.4. ER associated degradation (ERAD)
ERAD is a process by which misfolded ER proteins are detected and prevented
from progressing along the secretary pathway by ER-resident factors and
directed to the translocon for retrotranslocation (or dislocation) into the cytosol,
where they undergo ubiquitin- and proteasome-dependent degradation (41).
Acting as “mannose timer”, EDEM (ER degradation-enhancing α-mannosidaselike protein) is responsible for removing the glycoproteins, which could not be
productively folded, from the calnexin cycle. Futile recycling of terminally
misfolded proteins is prevented by EDEM, most likely EDEM3, which
successively cleaves mannose moieties from the glycan, eventually removing the
mannose that is normally re-glucosylated by UGGT. In complex with the protein
disulfide isomerase ERdj5 and BiP (42), EDEM produces Man7 N-glycan with a
terminal α 1,6-linked mannose, providing the targeting signal for ERAD (43). The
formation of the Man7 N-glycan is a key step in directing glycoprotein substrates
for ERAD. The lectin OS9 and the related XTP3-B recognize the Man7 N-glycan
and bring them to form complex with ubiquitin protein ligase, the Hrd1 E3/SEL1L
protein, and with the ER HSP90 homolog GRP94 and BiP, which help sequester
the misfolded protein away from other interactions until retrotranslocation (44).
Eventually, the misfolded proteins are retrotranslocated, ubiquitinated, and
degraded by the proteasome.
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Figure 1-2: ER quality control of newly synthesized glycoproteins (45).
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Nascent chains enter the ER lumen through the Sec61 complex and are core
glycosylated by the oligosaccharyltransferase (OST). The two terminal glucose
residues are rapidly trimmed by sequential action of the glucosidase I and II (step 1).
Mono-glucosylated N-glycans mediate the initial association of the folding
polypeptides with the ER lectin chaperones calnexin and/or calreticulin, resulting in
the exposure to the glycoprotein-dedicated oxidoreductase ERp57. It is likely that
most glycopolypeptides are released from calnexin/calreticulin/ERp57 in a native,
transport competent state (step 2). They are rapidly deglucosylated and partially
demannosylated (step 3) and eventually sequestered in transport vesicles for export
from the ER (step 4). For a fraction of newly synthesized glycoproteins, folding is not
completed in a single round of association with calnexin/calreticulin (step 2a). The
folding intermediate released from the lectin chaperones is deglucosylated (step 3a),
but its forward transport is inhibited by GT1. GT1 adds back a glucose residue (step
4a) only to glycoproteins with nearly native conformation. This second chance of
binding to calnexin/calreticulin facilitates additional folding attempts which likely
consists disulfide reshuffling. Glycopolypeptides released from calnexin and
displaying major folding defects are ignored by GT1 (step 3b). Rather, they attract
BiP, which are extensively demannosylated and dislocated across the ER membrane
for proteasome-mediated degradation (step 4b).

1.1.5. The unfolded protein response (UPR)
Accumulation of misfolded proteins in the ER triggers the unfolded protein
response

(UPR)

that

signals

compensatory mechanisms

to

keep

ER
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homeostasis, including up-regulation of ER chaperones and down-regulation of
protein translation (46, 47) (Figure 1-3).
The UPR is a highly conserved intracellular pathway that was originally
discovered in yeast. The proximal sensor of ER stress in yeast is the inositol
requiring enzyme-1 (Ire1). Ire 1 contains a unique endoribonuclease activity in its
cytosolic domain, which carries out the unconventional splicing of Hac1 mRNA
(48). Hac1 mRNA is found constitutively in the cytosol, where its native
nucleotide sequence is inefficiently recognized and translated. In response to ER
stress, this transmembrane protein is dimerized and trans-autophosphorylated to
be activated (49). The activated endoribonuclease on Ire1 splices out a specific
intron causing a frame-shift in the Hac1 nucleotide sequence. The new
nucleotide sequence is recognized and efficiently translated into the transcription
factor Hac1p (48). Hac1p subsequently enters the nucleus and induces the
genes which aid in folding and degradation of unfolded/misfolded proteins.
Although there are α- and β-alleles of both IRE1 and ATF6 in the
mammalian genome, only IRE1 α is expressed in all tissues and only ATF6 α
signals the UPR. IRE1 α is selectively expressed in intestinal epithelial cells and
it is not known which genes are regulated by ATF6 α. IRE1 activation elicits an
endoribonuclease function that induces non-conventional splicing of Xbp1
mRNA. Splicing of Xbp1 mRNA, the only known splicing substrate of IRE1,
removes a 26-base intron that alters the translation reading frame to produce a
highly active bZiP transcription factor that activates genes encoding ER protein
chaperones, lipid biosynthetic enzymes, and ERAD functions (50-52). Upon
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release from BiP, ATF6 traffics to the Golgi complex where it is cleaved by the
S1P and S2P processing enzymes to produce a cytosolic fragment that activates
transcription of genes providing complementary and overlapping functions with
those activated by XBP1 which restores productive ER protein folding and
increases ERAD. Indeed, cells deleted in either Ire1 α, Xbp1 or Atf6 α are
defective in ERAD (53, 54).
The UPR plays an important role in functions to regulate a cell’s folding
capability in response to developmental demands or physiological changes.
Especially, in cell types with a high secretary load or an ER compartment that is
uniquely susceptible to stress, the UPR becomes vital for cell survival and
function (50, 55). In response to the ER stress, UPR proteins act in a coordinated
fashion to initially decrease general protein translation and subsequently
increase transcription of genes that encode proteins that aid in both protein
folding and degradation. Therefore, pathological conditions interfering with ER
homeostasis and resulting in prolonged activation of the UPR could lead to
various diseases (56, 57).
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Figure 1-3: Signaling the unfolded protein response (UPR) (58).

The UPR in mammalian cells is far more complex than that in yeast and appears to
act both at the level of transcriptional as well as translational regulation (3).
Mammalian cells have three ER membrane bound proximal sensors. They are the
mammalian homologue of yeast IRE1, protein kinase R like ER protein kinase
(PERK), and activating transcription factor 6 (ATF6) (Figure 1-3) (4, 5). The three
UPR sensors are maintained in an inactive state through interaction with the protein
chaperone BiP. It is proposed that as unfolded proteins accumulate, bind, and
sequester BiP, they promote BiP dissociation from PERK, IRE1, and ATF6 (1, 7). BiP
release

from

IRE1

and

PERK

permits

their

homodimerization,

trans-

autophosphorylation, and activation. Activated PERK phosphorylates the α-subunit
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of the translation initiation factor 2 (eIF2 ), leading to rapid and transient inhibition of
protein synthesis (1). eIF2 is a heterotrimeric GTPase required to bring initiator
methionyl tRNA to the ribosome for AUG initiation codon selection (2).

1.2.

Protein expression and refolding technologies
Biomedical and structural biology studies of proteins require large quantities

of purified proteins. Over the past several decades, protein expression systems
(Escherichia coli, baculovirus-mediated insect cell, Saccharomyces cerevisiae
and several mammalian based systems) have been developed for large-scale
recombinant protein expression. Each of these systems has its strength and
weakness (yield, proper folding, post-translational modifications, etc).

1.2.1. Prokaryotic expression system
Escherichia coli is the simplest and by far the most widely used organism
for protein expression. Our lab also developed a very high yield bacterial protein
expression system that produce nearly gram quantity of pure recombinant
proteins from one liter of bacterial culture (59). Many recombinant proteins have
been successfully produced in bacteria; however, reports note that ectopically
expressed proteins especially those that are cystein-rich, have basic isoelectric
points (pI), and that are less than 10 kDa or greater than 50 kDa have overall
reduced success rates in traditional purifaction schemes (60). Other factors such
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as improper folding, protein aggregation (inclusion body formation), and lack of
proper eukaryotic post-translational modifications (PTMs) of the ectopically
expressed proteins could potentially affect their conformation, stability, and
function. All of these possible limiting factors reduce the usefullness of bacterial
protein expression systems, especially for eukaryotic proteins where the success
rates are typically lower (61-64).

1.2.2. Eukaryotic expression system
The yeast strain, Saccharomyces cerevisiae is an expression system that
has the advantage that can produce proteins in a more native eukarytoic
environment but with reduced yield, a common drawback of eukarytoic
expression systems.

Another drawback is the S. cerevisiae glycosylation

pattern, which is very different from its mammalian counterpart, and commonly
involves hypermannosilation that potentially affects the proper folding and activity
of heterologously expressed mammalian proteins.
Insect cell is another common recombinant protein production system.
Appreciated advantages of insect cells are the robust and relatively inexpensive
cell culture and the fact that most eukaryotic PTMs are executed properly (65).
However, the baculovirus expression system requires multi-step process to make
the viruses and the need to maintain high virus titers which sometimes can be
quite challenging (66). Furthermore, the protein expression yield of this insect cell
system is low.
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For expressing physiological proteins, including therapeutic proteins,
mammalian cell lines, such as CHO or HEK293, are widely used because they
offer a cellular environment closer to the native condition. However, the yield of
this system is quite low. The expression levels of purified recombinant protein are
usually in the microgram quantity (67) and expression cost of mammalian cell
protein expression is quite high. This expression system weighs the fidelity of
PTMs, correct folding and processing in mammalian cells against their slow
doubling rates, potentially inefficient transfection, overall lower productivity and
their dependence on expensive reagents, such as serum (68).

1.2.3. Protein refolding in vitro
Protein studies and protein therapeutics need large quantities of properly
folded and biologically functional proteins. Genetic engineering allows rapid and
reliable production of heterologous proteins via recombinant methods, in
particular, bacterial expression methods. These methods are used to induce cells
to overexpress a target protein. Overexpressed proteins, however, often form
“inclusion bodies”, the macroscopic aggregates in cells, especially for the
prokaryotic

expression

system.

Therefore,

the

ultimate

success

of

overexpression strategies sometimes depends on the refolding rate of properly
folded native states of aggregated proteins in the bacterial inclusion body.
Therefore, protein refolding in vitro is important.
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The first milestone to explore protein refolding in vitro emerged when
Christian Anfinsen and his colleagues in the 1960s demonstrated that simply
removing denaturant is sufficient for a fully denatured protein to refold (69). This
work demonstrated that all the driving forces and guiding information are
embedded in the primary amino acid sequence of a protein and no external
template is required. Also, this study showed, just like other processes in nature,
protein folding needs energy, a process following the universal thermodynamics
law. Intrinsic protein refolding steps include secondary structure formation, longrange tertiary contacts, interaction of hydrophobic groups, interaction of hydrogen
bond donor/acceptor, side-chain packing, and other processes. Conformational
entropy and several major interactions, such as the hydrophobic effect, hydrogen
bonds, electrostatic interactions, and van del Waals forces, contribute to protein
refolding.
Conformational entropy is the major energy term opposing protein folding
because entropy is a measure of the degree of randomness or disorder in a
system. As the folding reaction proceeds, the conformational entropy eventually
decreases as the unfolded state of protein has the highest conformational
entropy, whereas the folded protein has the lowest conformational entropy. The
loss of entropy starts to be compensated by the favorable hydrophobic and other
interactions.
Based on the theory, a protein always folds into the conformations, which
achieve the lowest possible energy. An energy landscape of protein folding
(Figure 1-4) provides a statistical description of the folding process. It proposes
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that proteins fold in an ordered way and the whole structure ensemble process is
an energy-biased folding pathway (70-72). However, this funneled energy
landscape theory fails to provide clues as to the guidance to the folding reaction
happening inside living cells. Even though the folding reaction can proceed
through a multitude of distinct routes to reach the lowest energy native state as
described in the energy landscape theory (73-77), proteins do not find their
native conformation from an endless number of potential three-dimensional
probabilities that it could randomly fold into. The protein folding process in living
organisms occurs in a second time scale (78). Localized interactions with
molecular chaperones and enzymes inside of cells guide and speed up the
folding process.

Figure 1-4: The energy landscape depiction of protein folding (72) .
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1.2.4. In vitro protein refolding techniques
Protein misfolding frequently happens when expressing recombinant
proteins in a foreign cell as well as inside mammalian cells under certain
physiological conditions. Experimental approaches have been developed to
refold aggregated proteins into their biologically active forms. The following
briefly summarizes these protein refolding techniques:

1.2.4.1. Direct dilution
The simplist of these procedures is the direct dilution method. Diluting the
protein reduces intermolecular interactions, denaturants, etc. that could
contribute to protein aggregation. However, a major drawback of this technique
is that the protein is highly diluted and needs to be concentrated. Concentrating
may contribute to the reaggregation of the protein.

1.2.4.2. Dialysis
Similar to the direct dilution technique, dialysis can remove potential
denaturants allowing the unfolded protein to achieve its native conformation. In
contrast to the direct dilution method, the change from denaturing to native buffer
conditions occurs gradually allowing the protein to slowly reach its native state.
However, through this process the unfolded protein may pass through several
different folding intermediates, some of which are unproductive and even could
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protentiate protein-protein interactions promoting aggregation (79).

As the

protein concentration remains relatively stable during this procedure, a potential
benefit; however, may contribute to promoting the aggregation and thus making
protein aggregation a frequent problem of dialysis as compared to the direct
dilution method. Additionally, refolding yields can be negatively affected by nonspecific adsorption of protein to the membrane. However, for some proteins and
with the appropriate denaturant removal rates, adapted to the requirements of
the target protein, high refolding yields at high protein concentrations can be
obtained (80).

1.2.4.3. Chromatographic methods for protein refolding
1.2.4.3.1. Protein refolding based on size exclusion chromatography
Similar to both the direct dilution method and dialysis, buffer exchange for
denaturant removal can also be carried out using size exclusion chromatography
(SEC). SEC has several major advantages. The denaturant can be gradually
removed through use of a concentration gradiant allowing the denatured protein
to refold. As with dialysis, protein aggregation can be a problem. However, the
power of SEC allows enrichment of the properly folded protein over the misfolded/aggregated intermediates by taking advantage of the mobility differences
based on size, shape, etc. of the target versus the folding intermediates.
Additionally, SEC also allows concomitent concentration and purification of the
folded protein. However, reduced yield of the folded protein, due to aggregation,
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could occur.

Also, the success of SEC depends on the properties of the

chromatographic resin to allow efficient separation of the renatured target protein
from different folding intermediates, misfolded protein, and aggregates that might
form during the refolding process (81).

1.2.4.3.2. Assisted protein refolding using affinity chromotography
In this technique, the unfolded protein is attached to a solid support
(matrix material of the column) through a variety of methods such as ‘tagging’ the
protein (eg. Histidine tag) or using ion-exchange or hydrophobic chromotography
based methods if the biochemical properties of the protein are known. Proteins
containing artificially engineered peptide tags such as the hexahistidine tag can
bind to immobilized metal ions.

After binding, the matrix-protein complex is

brought to refolding conditions by replacing the denaturing buffer condition with a
native one. Finally, the refolded protein can be detached from the matrix, e.g. in
the case hexahistidine-tagged proteins by elution with EDTA or imidazole or by
buffers with high ionic strength in the case of proteins bound by ionic interactions
(82). Due to the selective binding, matrix-assisted refolding can combine the
renaturation of the target protein along with its purification (83).

However,

copurification of the aggregated/mis-folded proteins side-by-side with the
refolded protein could occur and may become representative. If predominant,
these aggregated/misfolded proteins could interfere in strutural studies and thus
need to be removed and the purification can be accomplished with SEC.
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1.2.4.3.3. Refolding using hydrophobic interaction chromatography
Hydrophobic interaction chromatography (HIC) has also been successfully
used for protein refolding with concomitant removal of contaminating proteins
during the renaturation process (84). Unfolded proteins are applied to the column
at high salt concentrations and refolded and eluted with a decreasing salt
gradient. It has been proposed that refolding is facilitated during HIC because
unfolded proteins adsorb at high salt concentrations to the hydrophobic matrix
and, thus, are not prone to aggregation. Additionally, hydrophobic regions of the
protein that adsorb to the HIC matrix form micro domains around which native
structure elements can form. During migration through the column, the protein
will pass through several steps of adsorption and desorption, controlled by the
salt concentration and hydrophobicity of the intermediate(s), resulting finally in
the formation of the native structure (85).

1.2.4.4. Physical conditions and chemical additives that influence protein
folding
Several physical variables, such as temperature, pressure, and solution
phases, can impact protein folding. Temperature has general effects on the rate
of protein folding. In general, higher temperatures increasing the rate of folding
but also the propensity towards aggregation whereas lower temperatures reduce
the folding rate and can increase the amount of properly folded proteins (86).
For example, growing bacteria at temperatures slightly lower than 37°C during

28

the protein induction phase can reduce inclusion body formation (and hence
aggregation) for some proteins (87).
Another physical property affecting protein folding is pressure. Protein
aggregation can actually be reversed by increasing pressure up to 3 kbar.
However, above 5 kbar the benefit may be lost as a loss in secondary structure
may occur (88). Slowly reducing the pressure back to ambient condition may aid
the folding process (89, 90).
At some point, in vivo, some proteins, such as integral membrane
proteins, come into direct contact with or are transported through lipid
membranes (91). Detergents and phospholipids, in the form of micelles and
liposomes can aid protein refolding in vitro by mimicking the effect of a bilayered
membrane. Such methods can solubilize purified membrane proteins enabling
their proper folding.

Interestingly, in an alternative approach, denatured

hydrophilic proteins can be forced to fold as independent units in a reverse
micelle-type system. Once transferred to this solution, the protein tries to avoid
the organic phase. After reaching the hydrophilic core of the reversed micelle,
proteins can refold as a single molecule (92).

Both the micelle and reverse

micelle approaches aid protein folding of integral membrane and hydrophlic
proteins, respectively, mainly be preventing unwanted intermolecular proteinprotein interactions that can lead to aggregation.
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1.2.4.5. In vitro approaches to fold proteins containing disulfide linkages
Folding proteins that harbor disulfide bonds require special considerations.
Reducing agents such as dithiothreitol or β-mercaptoethanol must be added in
order to break the incorrect disulfide linkages. Slowly removing the reducing
reagent, such as during dialysis or direct dilution, can enable the protein to
sample several different disulfied linked states until the most stable one (native)
is found. Although this method works well for proteins with few disulfide bounds,
proteins with multiple cysteine residues require special considerations as
incorrect stable interactions are more likely to occur. For example, the ligandbinding domain of apolipoprotein E receptor 2, which has 42 cysteine residues, is
extremely difficult to refold in vitro (93).

Similar to the in vivo environment,

approaches utilizing protein chaperones to aid in the folding of multiple disulfide
linked proteins has found some promise in folding these difficult proteins. Protein
disulfide isomerase (PDI) is a folding catalyst that assists disulfide bond
formation in vivo and has found success for aiding disulfide bond formation
during in vitro protein folding. Although PDIs significantly increase the refolding
rate, much of the protein may still not be properly folded (albeit much improved)
resulting in reduced recovery of the properly folded protein. Additionally, residual
concentrations of chaotropic agents in the refolding buffer, especially
guanidinium hydrochloride, drastically reduce PDI activity and hence the protein
yield (94, 95).
Although attempts have been made to mimic the in vivo environment to
enable protein folding in vitro, the in vivo environment is still ideal.
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Overexpressing proteins in bacteria and refolding the proteins in vitro may
produce greater yields; however, some eukaryotic proteins cannot be refolded
with this approach. Alternatively, in an eukaryotic environment, these proteins
can be properly folded (aided by the eukaryotic folding machinery, 1.1.3.) but at a
dramatically reduced yield. For this reason, our lab has created a novel protein
delivery method that takes advantage of the high yield of the bacterial and the
high fidelity of the eukaryotic expression systems to refold difficult proteins, such
as the ligand-binding domain of apolipoprotein E receptor 2, to their native
structure.

1.3.

Protein delivery technology
Protein delivery techniques deliver biologically active proteins inside live

cells for cell biology studies and therapeutical applications. The most popular
means to deliver proteins into cells include electroporation, microinjection, the
construction of viral fusion proteins, and the use of cationic liposome.
Electroporation was initially used to introduce foreign DNA into eukaryotic
and bacterial cells (96). Scientists later found that

proteins could also be

introduced into cells using the same method (97-99). Cells are electroporated in
a buffered solution harboring the purified protein of interest. High-voltage electric
pulses result in the formation of small pores in the cell membrane. Proteins enter
the cell via these small pores or during the process of membrane reorganization
as the pores close and the cells return to their normal state. The efficiency of

31

delivery depends upon the strength of the applied electrical field, the length of the
pulses, temperature, and the composition of the buffered medium. Although this
method is successful with a variety of cell types, it has a few major drawbacks.
The overall yield of the protein after repurification from the transduced cells is
often negligible and the process can be damaging, causing cell death.
Another method used in the delievery of macromolecules (protein or nucleic
acid) into live cells is microinjection.

Microinjection was originally used to

introduce DNA directly into the nucleus of a cell where it can integrate directly
into the host cell genome, creating an established cell line bearing the gene of
interest (100). Proteins, such as antibodies and mutant proteins, can also be
directly delivered into cells via microinjection inorder to determine their cellular
effects (101, 102). This method has the advantage of directly introducing proteins
into specific cellular compartments; thereby, bypassing and preventing exposure
of the delivered protein to extreme microenvironments found within various
cellular compartments, such as the low-pH endosome. However, microinjection
requires extensive training and specialized equipment, which is normally not
available in most laboratories.
Several viral proteins or peptides have the ability to travel through cell
membranes
pathways.

independent of

classical receptor- or endocytosis-mediated

Membrane fusion proteins, such as the HIV-1 TAT proteins, the

herpes simplex virus 1 (HSV-1) DNA-binding protein VP22, and the Drosophila
Antennapedia (Antp) homeotic transcription factor, have the ability to penetrate
through the plasma membrane and into cells (103). The small protein
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transduction domains (PTDs), also known as cell-penetrating peptides (CPPs),
from these proteins can be fused to other proteins of interest to aid their delivery
into cells (103). Sequence alignment of the PTD shows a high basic amino acid
content (Lys and Arg), which may facilitate interaction of PTD with negatively
charged lipids on the cell surface. The advantage of this method is that protein
entry is rapid and works with many cell lines (104). However, the drawback to all
of the PTD-mediated protein delivery systems is that the transduction domain
must be covalently attached to the protein being delivered. Thus, it is necessary
to design special vectors and limit the size of the cargo protein because of the
relatively large PTDs. Also, denaturation or inactivation of proteins was observed
after PTD fusion, especially for TAT. Reduced yield after re-purification of the
PTD protein fusion can also be a major problem since degredation can occur if
the PTD-fused protein is misfolded, thus significantly reducing the delivery
efficiency. Furthermore, the PTD-based protein delivery method does not have a
targeting capability and cannot specifically delivery a protein into the desired
intracellular compartment, raising concern about the physiological relevance of
the delivered proteins (104).
Liposomes are known for their ability as vehicles to deliver macromolecules
into cells (105, 106). Cationic liposome can spontaneously and efficiently form
complexes with negatively charged cargo, facilitating the delivery. This strategy
has been successfully applied to protein delivery (107). But the physical
characteristics of the cargo, such as the electric charges and hydrophobicity, can
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influence the extent of the interaction between the cargo and the cationic
liposome and ultimately impact the delivery efficiency.
Our lab recently developed an innovative protein delivery technology, based
on the QQ-reagent, a polyethylenimine (PEI)–based cocktail, with a unique
formulation of lipids and enhancers (Figure 1-5). It is compatible with most types
of cell culture media and non-covalently binds the protein cargo of interest. This
protein delivery technology is rapid and straightforward. The protein of interest
can be produced by highly efficient E. coli expression systems and purified under
denaturing conditions from inclusion bodies. The QQ-cocktails can efficiently
dissolve the target proteins in delivery buffer that contains urea and modify them
for protein delivery. Another important advantage of QQ-protein delivery
technique is that it can deliver labeled protein inside mammalian cells, which
makes in vivo NMR and fluorescence studies potentially possible. More
importantly, the QQ-protein delivery technique has several novel features that
significantly distinguishes it from all the other protein delivery techniques
currently available (Figure 1-5) The novel features of the QQ-protein delivery
technique ensure the physiological relevance of the delivered proteins, which is
indistinguishable from the endogenous proteins. Thus, the QQ-protein delivery
technique can have many applications in cell biology.
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Figure 1-5: The technical flow-chart of the QQ- protein delivery system.

1.3.1. The QQ-reagent
Dr. Qianqin Li in our lab recently develoed a very efficient QQ- protein
delivery system (the following data on QQ- reagents were done by Dr. Qianqian
LI). In this protein delivery system, the QQ- reagent plays the key role. It is a
cocktail of polyethylenimine (PEI) with unique combinations of lipids and
enhancers. Table 1-3 shows examples of different formulations of the QQreagent. The mechanism of protein delivery by QQ-reagent is unclear. However,
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PEI is well known for its efficient binding to negatively charged DNA and
mediating the transfection of eukaryotic cells (108). PEI is highly basic harboring
many amino groups. The amino groups are protonated at neutral pH and noncovalently bind negatively charged macromolecules to form a cationic complex.
The cell surface is normally negatively charged due to the presence of
glycoproteins, proteoglycans, and sulfated proteoglycans (109-111).

These

features can mediate interactions between the cell membrane and the cationic
complex and promote uptake of the QQ-modified proteins (112, 113). The lipid
composites and enhancers facilitate the solubility of the delivered proteins, such
as membrane proteins, and help the formation of delivery vesicles, greatly
enhancing the delivery efficiency of QQ-reagent protein delivery system.
Table 1-3: Recipes for different QQ reagents from the stock solution of
cation reagents, lipids and enhancers (Courtesy of Dr. Qianqian Li).
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a.

2 kDa, 8 kDa, 12 kDa, 25 kDa and 60 kDa represent the different molecular

weights of PEI.
b. Total volume is 5 ml when preparing the QQ reagents. We also dissolve the
protein at a concentration of 0.2-8.0 mg/ml, depending on protein solubility and the
purpose of the studies.
c. In our hand, 2 kDa produces the least cellular toxicity whereas 60K produces the
most cellular toxicity.

A concentration of 50 ug/ml of the QQ modified protein is optimal for
relatively high protein delivery efficiency. A mixture of QQ modified protein,
serum-free medium, and protease inhibitor is incubated with the mammalian
cells, which have been seeded for 2-5 days to reach 80-90% confluency, for 0.54 hours, application dependent. The cells are extensively washed to remove the
undelivered protein.

With complete growth medium, the cells are ready for

further experimentation.

1.3.2. High protein delivery efficiency
QQ-protein delivery has been tested using different proteins, covering a
wide range of molecular weights, isoelectric points (pIs), and solubility, including
two membrane proteins. Table 1-4 lists the 17 proteins, their properties, and their
protein delivery efficiency using QQ-protein delivery.
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Table 1-4: Proteins, their properties, and protein delivery efficiency using
QQ-reagent protein delivery system (Courtesy of Dr. Qianqian Li).

Figure 1-6 shows the SDS-PAGE (Left panel) and Western blots (right
panel) of QQ-modified receptor-associated protein (RAP) that was delivered into
Hela cells. RAP is an ER resident molecular chaperone of the LDLR family
members, including apoER2 and VLDLR. RAP binds tightly to the receptors at
neutral pH, acting as a universal antagonist of the ligand binding domains. It also
escorts the LDLR family members in the early stage of secretary pathway in the
ER, reducing premature ligand binding and receptor aggregation. Detailed
background information will be given in Chapter II. For now, RAP will be used as
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an example to demonstrate the efficient protein delivery of the QQ-reagent. The
grey arrow shows the protein band of bacterially expressed RAP, while the black
arrow shows the protein band of RAP in the Hela cell lysate after protein delivery
(Figure 1-6). Compared with the control Hela cell lysates (without protein
delivery) (lane 1), an additional band of roughly 40 kDa was observed in the Hela
cell lystes (lanes 2 and 3) of cells preincubated with QQ-modified RAP. The
Western blot (Right panel) confirms that this band corresponds to RAP (compare
lane 1 (control) to lane 2). In addition, the band intensity of lane 2 was estimated
to be at least twice as strong as that of lane 3, where 0.25 mg/ml of purified
bacterially expressed RAP was loaded. This suggests that at least 0.5 mg/ml of
the QQ-delivered RAP was recovered, demonstrating the efficiency by the QQreagent.

Figure 1-6: High protein delivery efficiency of QQ-reagent modified proteins
(Courtesy of Dr. Qianqian Li).
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Left: A 10% SDS-PAGE quantitatively showing high efficiency of the QQ-delivered
RAP. Lane 1: Hela cell lysate without RAP delivery. Lane 2: 5 ul Hela cell lysate with
RAP delivery for 1 hour. Lane 3: 10 ul Hela cell lysate with RAP delivery for 1 hour.
Lanes 4-7: 60, 120, 250 and 500 ug/ml of RAP (20 ul). Right: A Western blot using an
anti-RAP antibody. Lane 1: Hela cell lysate without RAP delivery. Lane 2: 5 ul Hela
cell lysate with RAP delivery. Lane 3: 0.25 mg/ml bacterial expressed RAP in 5-ul.
Gray arrow: the bacterial expressed RAP. Black arrow: the HeLa cell loaded RAP.

1.3.3. Protection of the QQ-delivered proteins from intracellular protease
degradation
In order to see the stability of QQ-modified protein inside of mammalian
cells, MESD, a 195-residue specific protein chaperone for the LDLR family (114)
(115), was QQ-modified and tested for stability against protease degradation by
adding protease cocktail into MESD solution (Figure 1-7), which is either
modified without (lanes 1-4) or with (lanes 7-10) the QQ-reagent. As compared
to without protease treatment (lane 5), the protein modified with the QQ-reagent
(lanes 7-10) showed significantly less degredation as compared to the absence
of the QQ-modification (lanes 1-4). These results suggest that the QQ-reagent
can protect MESD from protease degradation and theoretically from intracellularmediated degradation.

Basically, the QQ-reagent may protect the modified

protein from degradation upon entering into the cell; however, the underlying
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mechanism is not well understood. This may enable the protein to refold and to
obtain high yields of repurified protein.

Figure 1-7: QQ-reagent protects MESD from the protease-mediated
degradation in vitro (Courtesy of Dr. Qianqian Li).

Lane 1-4: MESD without QQ-modification. Lane 7-10: the QQ-modified MESD. While
reacting with 1.4 mU/ml protease cocktail for 0 hour (Lane 1 and Lane 7), 1 hour
(Lane 2 and Lane 8), 2 hours (Lane 3 and Lane 9), 4 hours (Lane 4 and Lane 10),
QQ -modified MESD showed relatively higher stability than the unmodified one. Lane
5: MESD without reacting with protease cocktail. Lane 6: The QQ-reagent.

1.3.4. Targeting capability of the QQ-protein delivery technique
In order to visualize the trafficking of delivered proteins, in this

case

MESD, a resident ER protein, inside mammalian cells and to detect their final
location, a small red fluorophore (ArrayIt Red640, Molecular Weight = 799.8 kDa)

41

was linked to MESD. The labeled MESD is modified with QQ-reagent and
delivered inside of Hela cells. After 2 hrs post-delivery, MESD is predominantly
localized to the perinuclear areas, which are potentially the ER (Figure 1-8A). To
further confirm that this perinuclear localization of MESD was , in fact, to the ER,
a co-localization experiment was performed. Transient transfection of a GFP-ER
marker (green) cDNA into BSC-1 cells is conducted following the published
protocol (116, 117). After 72 hrs, the transfected cells were incubated with QQmodified MESD labeled with ArrayIt Red640 (red). After 2 hrs following protein
delivery, the cells were subjected to fluorescence imaging, showing a merge of
both the red and green chanels, along with the light microscopy image (Figure 18a). Yellow fluorescence was detected around the perinulear locations, indicating
MESD was indeed localized to the ER.
The QQ-reagent was also able to correctly direct the membrane protein
peripheral myelin protein 22 (PMP22) and the transcription factor Oct4 to their
appropriate intracellular compartments, the plasma membrane and the nucleus,
respectivley. PMP-22 was labeled with the ArrayIt Red640 (red) and delivered
into Hela cells using QQ-protein delivery. Fluorescence imaging of a Hela cell
shows that a majority of the red fluorescence signals are localized to the plasma
membrane (Figure 1-8B and b).

To study intracellular location of the QQ-

delivered Oct4, the bacterially expressed Oct4 was labeled with a small
fluorophore DyLight 488 (green), QQ-modified, and delievered into human
fibroblast cells. Fluorescence imaging data showed that the delivered Oct4 is
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predominantly localized to the nucleus, as it colocalized with the DNA stain, DAPI
(blue) (Figure 1-8 C and c).
Taking together, these results show that QQ-reagent delievered proteins
within the cell as evidenced by the correct in situ residential location of the QQmodified MESD, PMP22, and Oct4 to the ER, the plasma membrane, and the
nucleus, respectivley; otherwise, they would not be localized as such. This data
also suggests that the QQ-reagent does not influence the trafficing of these
proteins. Also, since these proteins were directed to their correct in situ cellular
compartments argues that these proteins are likely to be properly folded;
however, further experiments are needed to confirm this point. Overall, the QQreagent shows promise as a protein delievery system that can sucessfully
deliever proteins into cells.

Figure 1-8: Targeting capability of the QQ protein delivery technique
(Courtesy of Dr. Qianqian Li).
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(A) Fluorescence confocal image of the intracellular location of ArrayIt Red640
labeled MESD (red), merging with the light microscopy image of the same HeLa cell.
The arrows showed the perinulear localization of delivered MESD. (a) Fluorescence
confocal image of the co-localization of GFP-ER marker (green) and ArrayIt Red640
(red) labeled MESD in BSC-1 cells, after QQ-protein delivery.

(B) Fluorescence

confocal image of a typical HeLa cells after PMP22 transduction. PMP22 was labeled
with ArrayIt Red640 (red) fluorophore. The arrow showed the plasma membrane
location of PMP22. (b) A merging fluorescence confocal image of both Rhodamine
and CFP channels for the same HeLa cell.

(C) Fluorescence confocal image of

human fibroblast cell transducted with DyLight 488 (green) labeled Oct4. The arrows
showed its nucleus localization. (c) A merging fluorescence confocal image of both
DyLight 488 (green) labeled Oct4 and nucleus staining DAPI (blue) for the same
fibroblast cell.

1.4. An efficient bacterial expression system that produces gram quantity
of pure recombinant proteins
The gram-negative bacterium E. coli offers a means for rapid, high yield,
and economical production of recombinant proteins. However, high-level
production of functional eukaryotic proteins in E. coli may not be a routine matter,
sometimes it is quite challenging. Techniques to optimize heterologous protein
overproduction in E. coli have been explored for host strain selection, plasmid
copy numbers, promoter selection, mRNA stability, and codon usage,
significantly enhancing the yields of the foreign eukaryotic proteins. Our lab has
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been working on optimizations of bacterial expression conditions and media with
a focus on achieving very high cell density for high-level production of eukaryotic
proteins. Two high-cell-density bacterial expression methods have been
explored, including an autoinduction introduced by Studier (118) recently and a
high-cell-density IPTG-induction method developed in our lab, to achieve a celldensity OD600 of 10–20 in the normal laboratory setting using a regular incubator
shaker. Several practical protocols have been implemented with these high-celldensity expression methods to ensure a very high yield of recombinant protein
production. With these methods and protocols, a yield of 14–25 mg of NMR
triple-labeled proteins and 17–34 mg of unlabeled proteins from a 50-mL cell
culture is routinely achieved for all seven proteins tested. Such a high protein
yield used the same DNA constructs, bacterial strains, and a regular incubator
shaker and no fermentor is necessary. More importantly, these methods permit
for consistently production of such a high yield of recombinant proteins using E.
coli expression (59).
One of the major challenges to achieve high yield protein production is to
achieve a high cell density bacterial expression under routine laboratory setting
using a regular incubator shaker. A hybrid bacterial expression method has been
developed in our lab that utilizes rich medium to achieve a high cell density
before IPTG induction, while maintaining the advantage of the tightly controlled
induction by IPTG in minimal medium (59).

This hybrid expression method

allows us to reach a high cell density with a final OD600 that is 5 to 10 fold higher
than that of the regular IPTG induction method.
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High cell density culture systems, especially under the non-fermentation,
laboratory conditions, often cause a low or even no protein production with a high
cell density culture, since bacterial cells experience stress at a high cell density
using a regular incubator shaker which does not control the O2 level, pH and
nutrients of the expression medium. To solve this problem, several protocols
have been developed to ensure stability of plasmids inside bacterial cells during
high cell-density bacterial expression. These protocols include: (1) Proper
starting culture; (2) double colony selection; and (3) optimized time course and
temperature after IPTG-induction (59). In addition, cell areation and medium pH
during high cell-density expression are also optimized. With these protocols, a
gram/liter pure recombinant protein is achieved using our bacterial expression
method.

1.5.

Summary of literature review
Protein folding promotes a protein’s native conformation and biological

function. Misfolding can cause severe protein misfolding diseases, such as
Alzheimer’s disease, diabetes, cancer, and prion diseases. To study the protein
folding mechanism, techniques including X-ray crystallography and nuclear
magnetic resonance spectroscopy (NMR) are critical; however, large quantities
of properly folded and biologically functional proteins are required. The present
large-scale heterologous protein expression systems using E.coli, yeast, insect,
or mammalian cell lines have inherited weaknesses, often causing protein
misfolding. In vitro protein refolding techniques are the other option to obtain
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properly folded and biologically active proteins at relatively high speed and low
cost. But the efficiency of in vitro protein refolding is greatly affected by the
aggregation and misfolding reactions happening in the same refolding system.
Therefore, a more simple and cost-effective protein refolding technique is
needed.
Our lab recently developed a novel QQ- protein delivery technique. By
using the highly efficient QQ-protein delivery technique, we can deliver large
quantities of bacterially expressed proteins inside of mammalian cells. The QQreagent non-covalently attaches to the delivered protein, efficiently transports the
protein across the cell membrane, helps the delivered protein to evade
degredation, and targets the delivered protein to its in situ cellular location.
Our lab has also developed a highly efficient recombinant protein
expression method in an E. coli protein expression system. This method bases
on a hybrid high cell-density IPTG-induction bacterial expression with several
practical protocols to ensure high-yield production of protein. This novel bacterial
expression method allows us to routinely obtain nearly gram quantity of pure
recombinant proteins from a one-liter bacterial culture.
The ER is the cellular machinery of protein translation and protein folding.
High density of folding chaperones and enzymes exist in the ER, efficiently
assisting protein refolding. Simultaneously, the stringent quality control (QC)
system can guarantee only correctly folded proteins are sent to their final
destinations. By using our developed recombinant protein expression method
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and QQ-protein delivery technique, we can deliver large quantity of recombinant
proteins inside of mammalian cells. The ER protein folding machinery may be
able to refold them with the help of foldases and chaperones. The folded protein
can be repurified from the cells. The quality and quantity of purified refolded
protein can meet the need of many applications, such as structural biology and
protein therapeutics.

1.6.

Research goals
The goal of my dissertation reseach was to develop an in vivo protein

refolding technique that allows efficient refolding of bacterially expressed proteins
using the intracellular folding machinery of mammalian cells. The QQ-protein
delivery technique allows us to deliver the bacterially expressed proteins into the
ER, where the protein folding machinery of the cell may properly refold the QQdelivered proteins efficiently by recruiting chaperones and foldases. The ER
quality control system ensures that only the properly refolded, bacterially
expressed proteins will achieve maturity with the misfolded proteins being
degraded. Thus, this in vivo protein refolding technique may provide an efficient
strategy to refold large quantity of bacterially expressed proteins that are possibly
misfolded.
In particular, this technique may be specifically useful for the efficient
refolding of secreted proteins, since these proteins will be targeted for secretion
into the cell culture medium once they are properly folded and posttranslationally
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modified. Therefore, purification of the refolded proteins will be easy to achieve if
we use serum-free cell culture medium. In addition, by properly designing the
protein sequences, we can target protein domains and critical segments of an
intact protein causing them to be secreted by the cell. Thus, we can take
advantage of these domains and critical protein segments to allow secretion of
the protein of interest, which will be already somewhat pure as it is seperated
from the rest of the cellular millue, making it rather straightforward to efficiently
refold and purify them in large quantity. Finally, this in vivo protein refolding
technique may also have the capability to generate properly posttranslationally
modified proteins inside the ER and Golgi, sites where some posttranslational
modifications can occur.
To develop this in vivo protein refolding technique, two protein domains:
beta- propeller/EGF domain I of LDL receptor- related protein 6 (BP1-LRP6) and
the ligand-binding domains of apolipoprotein E receptor 2 (LBD-apoER2), will be
tested. BP1-LRP6 and LBD-apoER2 are protein domains of two large receptors
of the low-density lipoprotein receptor (LDLR)-family, with molecular weight of
34-36 kDa. Both proteins have large numbers of cysteins that form complex
intracellular disulfide bonds, which are important for their structural rigidity as well
as their biological function. In particular, LBD-apoER2 contain 298-residues that
has 42-cysteines, forming 21 intracellular disulfide bonds. This protein domain
also contains 7 Ca2+-binding sites. Refolding this protein domain is quite
challenging. Thus, these two protein domains are very good candidates to test
this in vivo protein refolding technique.
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Chapter II
Refolding of the Ligand-Binding Domain of Apolipoprotein E
receptor 2 (LBD-apoER2) inside mammalian cells
2.1.

Introduction
The aim of this project is to develop and optimize an in vivo protein

refolding technology that can be used to efficiently refold bacterially expressed
and potentially misfolded proteins using the ER folding machinery of mammalian
cells. Previously, our lab demonstrated that the misfolded proteins can be
delivered into mammalian cells using QQ-protein delivery and these delivered
protein can be refolded inside of cells. The refolded proteins display biological
functions and followed the same intracellular trafficking pathways (119). These
observations provide the solid foundation for this in vivo protein refolding
technology.
However, this in vivo protein refolding technique was in its early stage and
needed to be optimized so that it can be used to efficiently refold large quantities
of misfolded proteins and to produce properly folded, biologically functional
proteins. In addition, our optimization also focuses on proteins with complex
folding since the refolding of these kind of proteins are very challenging and in
most cases, the in vitro protein refolding techniques cannot be used to properly
refold these proteins. Our rationale is to utilize the intracellular folding machinery
of mammalian cells to efficiently refold these challenging proteins. Indeed, cells
have developed an efficient folding machinery and quality control systems,
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ensuring that only the proper folded proteins can escape the ER-associated
degradation system to reach their intracellular destinations or to be secreted
outside of the cells for function.
The QQ-protein delivery technique developed in our lab ensures that we
can efficiently deliver bacterially expressed proteins into the ER for refolding.
This solved a major problem for this project, since the QQ-protein delivery
provides us with the targeting capability to specifically and efficiently deliver the
proteins of interest inside the ER, such that these proteins have a chance for
refolding. The QQ-reagents are designed to non-covalently bind to the target
proteins and are hence reversible, enabling the unmodified protein, to have an
opportunity to be refolded by the ER resident machinery.
Our lab has been working on low-density lipoprotein receptor (LDLR)
family for several years. We are particularly interested in two domains of the
LDLR family: the ligand-binding domain and the YWTD β-propeller domain, since
these two domains are the two essential domains for biological functions of this
protein family. In order to perform research on these proteins, we first used
bacteria to prepare recombinant domains using the high cell-density bacterial
expression method recently developed by our lab (59). We found that although
our bacterial expression method produced large quantities of recombinant
proteins, these bacterially expressed domains were misfolded and not
biologically active. This is not surprising since both of the domains contain many
cysteines that form multiple intramolecular disulfide bonds. In addition, these
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domains also contain many Ca2+-binding sites. These structural features make it
very challenging to properly fold these domains.
However, these two domains of LDLR family provide good candidate
proteins for us to optimize our in vivo refolding technology. In this chapter, I will
focus on the refolding technique aimed at refolding the ligand-binding domain of
apolipoprotein E receptor 2 (LBD-apoER2), an LDLR family member. I optimized
several different parameters in an attempt to properly fold LBD-apoER2
including: the best QQ-reagent/LBD-apoER2 ratio for efficient delivery into the
ER, different cell culture conditions to facilitate refolding, and purification
procedure to isolate the protein after refolding. Through finding the best
conditions of this in vivo protein refolding technique, I was able to obtain properly
refolded LBD-apoER2.

Although the refolding efficiency of the QQ-delivered

LBD-apoER2 was only up to 20%, successive rounds of delievery enabled me to
get large quantitites of protein that I later purified. Most important of all, I was
also able to demonstrate that the purified LBD-apoER2 could bind to the ligands
of apoER2, suggesting that I obtained biologically active and hence properly
folded protein using this in vivo protein refolding technique.

2.1.1. LDL receptor superfamily
Lipoprotein particles mediate the transport of lipophilic molecules in both
the peripheral circulation system and within the central nerve system (CNS) to
maintain lipid homeostasis. These particles are typically spherical complexes of
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lipids and apolipoproteins. They can be recognized by the low-density lipoprotein
(LDL) receptors located on the cell surface for uptake.
The low-density lipoprotein receptor (LDLR) superfamily consists of over
ten known endocytic receptors, all of which share homology with the LDL
receptor. Most of these receptors are multifunctional, binding and endocytosing
many structurally and functionally distinct ligands. Together with the LDL
receptor, these receptors form the LDLR superfamily, primarily owing to their
structural homology, as well as functional redundancies.

Figure 2-1: Domain organization of human LDLR family members (120).
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Domains characteristic for the LDLR family are discussed in detail in the text. All
family members have a type I topology (i.e., N-terminus in the ER lumen or the extracellular space and the C-terminus in the cytosol) with the exception of LRP4. The
cytosolic domains contain one or multiple copies of NPXY, YXXL and di-leucine
based sequences that mediate internalization and intracellular sorting.

Figure 2-1 shows the domain organization of human LDLR-family. All the
members of the LDL receptor superfamily are composed of five major domains -- complement-like ligand binding repeats, epidermal growth factor (EGF) –like
repeats, YWTD β-propeller repeats, a transmembrane domain, and a short
cytoplasmic tail (121). A primary feature of this family is the presence of cysteinerich ligand-binding repeats, which form the ligand-binding domain (122-124).
These ligand-binding repeats, each of which is about 40 amino acids in length
and contains six cysteine residues, are also found in a number of complement
components and are therefore also referred to as complement-type repeats (CR)
or the LDL receptor type-A (LA) repeats.
The complex structures of LDLR superfamily members indicate that
biosynthesis of these receptors must require the assistance of molecular
chaperones. Indeed, studies with LRP, megalin, and VLDLR have shown that
RAP serves as a specialized chaperone to assist LDLR superfamily members to
fold correctly and then traffic safely within the early secretary pathway (125, 126).
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2.1.2. LDL receptor superfamily - structures
Extensive structural studies have been performed on individual domains of
LDL-receptor. For the ligand-binding domain, four ligand binding repeat
structures have been individually solved; only one is by X-ray crystallography, the
other three are by NMR (127). For example, repeat 1 consists of a beta-hairpin
structure, followed by a series of a beta turns with many of the side chains of the
acidic residues, including the highly conserved Ser-Asp-Glu motif, clustered on
one face of the module (Figure 2-2) (128, 129). Other ligand binding repeats
display a similar structure with subtle changes (127). The EGF precursor
homology repeat consists of 392 amino acids; there are three cysteine-rich
repeats (A, B and C), two at the N-terminus, and one at the C-terminus of YWTD
β-propeller repeats. In the middle, the YWTD repeats form a six-bladed βpropeller (Figure 2-2) (130).
In 2002, Rudenko et al. determined the crystal structure of the LDL
receptor domain I and II, residues 1-699, at pH 5.3 corresponding to the ligandreleased state (131) (Figure 2-3). Two histidines (H562, H586) in the β-propeller
point to repeats 4 and 5, and H190 from repeat 5 protrudes to the β-propeller
blades. Mutation of the three histidines did not affect the LDL-binding ability, but
LDL receptor loses its ability to release the bound ligand (132). It was
hypothesized that within the low pH of the endosome, the ligand-binding domain
of the receptor dissociates from its ligand, and transforms from its open state to
the closed state. Repeats 4 and 5 bend to contact the EGF precursor domain via
their calcium-binding loop (131), and the ligand binding domain flexibility for the
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Figure 2-2: Domain organization of the LDL receptor and regions within the
extracellular domain for which structural information has been obtained (133).

The O-linked sugar domain is thought to act mainly as a hydrophilic buffer zone that
keeps bound lipoprotein particles away from the lipid bilayer of the plasma
membrane. The NPxY motif in the cytoplasmic tail of the LDL receptor is required for
clustering and internalization. Boxed references next to structural representations
indicate the cited publication from which the respective structure has been
reproduced.
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A

B

Figure 2-3: The crystal structure of LDL receptor residue 1-699 at pH 5.3 (131).
(A) Cα trace of LDL-R monomer. Modules are colored according to their boundaries
with the ligand-binding domain containing R2 (residues 44 to 85), R3 (85 to 124), R4
(124 to 170), R5 (170 to 212), R6 (212 to 254), R7 (254 to 294), and the EGF
precursor homology domain containing A (294 to 332), B (332 to 377), β propeller
(377 to 643), and C (643 to 693). Regions of poor backbone connectivity are dashed.
Calcium ions are indicated as red spheres, and disulfide bonds and carbohydrates on
Asn135 and Asn251 are shown in gray as ball and stick (sulphur atoms, yellow; oxygen,
red; nitrogen, blue; and carbon, gray). (B) The view is rotated 90° from that of (A).
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open-closed state transformation is provided by the linker regions between seven
repeats instead of the connection of two domain (132).

2.1.3. LDLR superfamily – functions
The function that is most commonly associated with this evolutionarily
ancient family is cholesterol homeostasis. In humans, excess cholesterol in the
blood is captured by low-density lipoprotein (LDL) and removed in the liver by the
endocytosis of the LDL receptor (122, 124, 134). Recent evidence indicates that
the members of the LDL receptor gene family are active in the cell signalling
pathways between specialized cells in many, if not all, multicellular organisms
(135, 136).
Endocytosis is the process by which cells absorb molecules (such as
proteins) by engulfing them. The LDLR family plays a critical role in mediating
this important cellular process (Figure 2-4). The first step of endocytosis is for
molecules or ligands to bind to LDL receptors exposed at the cell surface. These
transmembrane proteins have the ligand-binding domain that recognizes and
binds to the ligands. The portion of the plasma membrane with bound ligand is
internalized by endocytosis. A drop in the pH (from ~7 to ~5) causes the LDL to
separate from its receptor. The vesicle then pinches apart into two smaller
vesicles: one containing free ligands such as LDLs; the other containing nowempty receptors. The vesicle with the LDLs fuses with a lysosome to form a
secondary lysosome. The enzymes of the lysosome then release free cholesterol
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Figure 2-4: LDLR biosynthesis and transport (137).
Briefly, LDLR is synthesized by the ER-associated ribosome and is folded inside the
rough ER and post-translationally modified inside ER and Golgi. The properly folded
and post-translationally modified LDLR translocates on the cell surface for function.
Upon binding to LDLR, the LDL-LDLR complex is endocytosed inside the cells via
clathrin-coated vesicles, which then travels to endosome. The low pH inside
endosome releases the LDL from LDLR. The released LDLR is recycled back to the
cell membrane for function, where the LDL is transported to lysosome for
degradation.

into the cytosol. The vesicle with unoccupied receptors returns to and fuses with
the plasma membrane, turning inside out as it does so (exocytosis). In this way
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the LDL receptors are returned to the cell surface for reuse. Various members of
the LDLR family display functional similarities (122, 124, 134).
One ligand, apolipoprotein E (apoE)-containing lipoprotein, binds most of
the receptors in the family, suggesting a role in lipid metabolism. Also, most
members of the LDLR family bind a 39 kDa receptor-associated protein (RAP)
(138). RAP is an endoplasmic reticulum (ER)-resident chaperone that functions
in receptor folding and trafficking along the early secretary pathway (125, 138,
139). Upon binding to the receptors following their translation, RAP promotes
proper folding and disulfide bond formation for members of the LDLR family. In
addition, RAP universally antagonizes the ligands binding to the receptors.
Because this later feature of RAP is believed to be important for escorting the
receptors and preventing pre-mature ligand binding during their exocytic
trafficking, the recombinant form of RAP has been extensively used in structural
and functional studies into the biology of the LDLR family members (138).
Recently, several independent studies have also demonstrated roles for
LDLR family members in cellular signaling (135, 136). For example, cellular
signaling through the VLDLR and/or apoER2 is important for the Reelin/disabled
pathway, which participates in neuronal cell migration during embryonic
development (140). In addition, LRP6 has been shown to be required for the Wnt
signaling pathway during embryonic development (141-143). Furthermore, a set
of cytoplasmic adaptor and scaffold proteins containing PID or PDZ domains,
including mammalian Disabled-1 (mDab1), mDab2, FE65, JNK-interacting
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protein JIP-1 and JIP-2, PSD-95, CAPON, and SEMCAP-1, binds to the
cytoplasmic tails of members of the LDLR family (136, 140, 144-146).
Members of the LDLR play roles in the pathogenesis of human diseases.
A classic example is mutation of the LDLR itself in the forms of familiar
hypercholesterolemia (FH) (147). The crucial role of the LDLR in cholesterol
homeostasis is indicated by the more than 1500 human mutations that have
been found in patients with familial hypercholesterolemia (FH) (148, 149). LRP5
and LRP6 are required for activation of the canonical Wnt signaling pathway for
cell proliferation and differentiation. Loss of Lrp5 is associated with delayed
mammary gland development and Wnt1 induced tumorigenesis. Functional
mutations in the Wnt co-receptor LRP5 also lead to osteoporosis-pseudoglioma,
while gain of function mutations lead to high bone mass disorders (150-153).
VLDLR and ApoER2 are obligate components of Reelin signaling pathway
essential for neuronal migration during development (154, 155). ApoER2
immunoreactivity in human hippocampus is present exclusively in neurons and is
increased in Alzheimers Disease (AD) (156). The c-Jun N-terminal kinase (JNK)
pathway may transduce Aβ neurotoxicity, and apoER2 binds JNK-interacting
proteins,

thus

suggesting

a

possible

involvement

of

apoER2

in

AD

pathophysiology (145).

2.1.4.

ApoER2
ApoER2 (apolipoprotein E receptor 2, also called LRP8, is a member of

the LDLR family (157). It is located on chromosome 1p34 and contains 19 exons,
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which span a genomic region of about 60 kb (157). ApoER2 is predominantly
expressed in brain and placenta (158). However, alternative splicing of the
apoER2 gene transcripts can give rise to different varieties of the apoER2
proteins from species to species or even from tissue to tissue within the same
organism.
ApoER2 consists of five domains that resemble those of the LDLR and the
very low-density lipoprotein (VLDL) receptor (157). Expression of apoER2 in 293
cells demonstrated that it is endocytosis competent (159). However, direct
comparison of the cytoplasmic domains of LRP, LDLR, VLDLR, and apoER2
overexpressed in CHO cells suggested a role in signaling rather than in
endocytosis (160). Studies have shown that apoER2 participates in transmitting
the extracellular Reelin signal to intracellular signaling processes initiated by
Disabled-1 (Dab1) (161). Reelin is an extracellular protein essential for the
development of laminated cortical brain structures in vertebrates (154). Upon
high-affinity binding to Reelin at the ligand-binding domain, apoER2 transmits the
Reelin signal to its intracellular domain and this signal underlies learning and
memory in the adult brain. ApoER2 appears to be the dominant Reelin receptor,
at least in the forebrain.
Later studies showed Reelin binds with high affinity to both apoER2 and
VLDLR (155, 161, 162), while Dab1 binds to the cytoplasmic NPxY motif of both
receptors through a PTB domain (144, 146). Importantly, all of the mice deficient
in both apoER2 and VLDL, or their ligand Reelin, or the adaptor protein Dab1
show markedly high levels of hyperphosphorylated tau protein, which are found

62

to accompany the formation of the neurofibrillary tangles that are one of the
pathological hallmarks of Alzheimers Disease (AD) (163). ApoER2 knockout
mice display disturbed neuronal organization in the hippocampus (164). ApoER2
immunoreactivity in human hippocampus is present exclusively in neurons and is
increased in AD (156). The c-Jun N-terminal kinase (JNK) pathway may
transduce Aβ neurotoxicity, and apoER2 binds JNK-interacting proteins, thus
suggesting a possible involvement of apoER2 in AD pathophysiology (145).

2.1.5.

Receptor-Associated Protein (RAP)
The complex structure of LDL receptors is highlighted by the presence of

clusters of cysteine-rich, ligand-binding repeats (165, 166). Recent studies have
shown that, under physiological condition, a 39 kDa receptor-associated protein
(RAP) RAP serves as a molecular chaperone to assist the lipoprotein receptor
folding and inhibit pre-mature ligand binding through LDL receptor secretary
pathway (125, 126). Human RAP is comprised of 323 amino acids. RAP has a
classical ER-signal sequence, a carboxyl-terminal tetrapeptide (HNEL) that is
similar to the ER-retention consensus sequence (KDEL) (165, 166). The
intracellular distribution of RAP was analyzed and quantified, showing
localization primarily within the ER (70%) and the Golgi network (24%) (167).
The most dramatic effect RAP is the inhibition of binding and/or uptake
of all other known LRP ligands (168-173). This ability of RAP distinguishes this
protein from other LRP ligands, which seldom inhibit one another’s binding or
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uptake. In addition to LRP, RAP also binds to other members of the LDLR
superfamily and inhibits ligand interactions. Studies have shown that RAP
exhibits high-affinity binding (KD~1-10 nM) for LRP, megalin, the VLDLR,
apoER2/LRP8 and LRP11/sorLA-1 (174). But relatively lower binding affinity
(KD~250 nM) was found for the LDLR (175-179).
RAP dissociates from the receptors at the lower pH environment of the
Golgi, which is consistant with its requirement of binding to LRP and Ca2+ at
neutral pH (169). Because of the N-terminal KDEL-like consensus, after
dissociating from receptors in the Golgi, RAP will be recycled back to the ER by
COPI coated vesicles (Figure 2-5) (139). All these special properties of RAP
define a novel class of molecular chaperones that selectively protect endocytic
receptors from ER associated degradation (ERAD).

RAP protects receptors

such as, the LDLR superfamily, by associating with the ligand binding domain of
the members of receptors early in the secretary pathway, reducing their ligand
binding

capacity

thereby

preventing

premature

ligand-binding

induced

aggregation, and their subsequent degradation in the ER. Figure 2-5 depicts
how RAP escorts receptors trafficking from the ER to the Golgi apparatus.

2.1.6.

Challenge of refolding LBD-apoER2
It is still unclear how individual domains of LDLR family folds into a

functional receptor. Disulfide bond formation and calcium incorporation are two
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dominant characteristics of ligand-binding domain of LDLR (LBD-LDLR) folding in
the ER. The newly synthesized LBD-LDLR polypeptide chains include seven

Figure 2-5: ER export and retrieval cycle of RAP- Role in LRP secretion (126).

LDL receptor-related proteins (LRP) are type I membrane proteins that undergo
cotranslational folding during translocation into the ER. Association with RAP
prevents premature ligand (Lig) binding in the ER. After transition into Golgi
compartments, RAP undergoes a conformational change, which is initiated by the
low-pH-induced charge reversal of histidines (Histidine switch). This partial unfolding
of RAP may also facilitate its interaction with the KDEL receptor, which mediates the
retrieval of RAP to the ER. The mildly acidic environment of the Golgi further
suppresses ligand interaction in the absence RAP, thereby ensuring proper sorting
and secretion of LRP and cosecreted ligands.
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ligand binding repeats that were demonstrated to be folded rapidly into compact
structures, containing non-native disulfide bonds linking distant regions of the
protein (180, 181). With time, the aid of molecular chaperones, and foldases in
the ER, the non-native disulfide bonds are reshuffled, allowing extension of the
molecule. Ultimately, in the native conformation, disulfide bonds only exist
between cysteine residues within individual ligand binding repeats (131). General
chaperones recognize and interact with unfolded, partially folded or misfolded
proteins due to common features such as exposed stretches of hydrophobic
amino acid residues, thereby preventing aggregation. The relatively oxidizing
environment of the ER may support disulfide bond formation, but the actual redox
reactions are catalyzed by oxidoreductases of the protein disulfide isomerase
(PDI) family (182-184).
Incorporation of calcium ions is the second major characteristic of LBDLDLR folding. These domains also have very high-affinity calcium binding sites.
NMR studies on the folding of repeat R5 demonstrated a strict correlation
between native disulfide bond formation and calcium binding (185). In the
absence of disulfide bonds, the calcium binding capacity is negligible. When the
distal disulfide bonds (non-native disulfide bonds) between cysteines II and V,
and IV and VI are formed, calcium will bind, but maximum affinity requires a
native structure.
Specialized chaperones, RAP and MESD/Boca may facilitate folding of
different domains of LDLR relatives. Whereas RAP improved the folding of the
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ligand binding domain of LDLR family (125, 186), MESD/Boca mainly act on
LDLR containing EGF-like repeats and YWTD β-propeller structures (115, 187).
The total seven ligand-binding repeats in the LBD-aopER2 contains 42
cysteines that form 21 disulfide bonds. Each ligand binding repeat in the ligand
binding domain (LBD) has three disulfide bonds. In addition, each ligand-binding
repeat also contains a Ca2+-binding site. Because of the complex array of the
disulfide bonding formation and Ca2+-binding within the LBD-aopER2, it is
impossible to refold the protein in vitro into the native conformation, especially
without the help of molecular chaperones and folding enzymes. Therefore,
refolding bacterially expressed LBD-apoER2 becomes extremely challenging. To
our knowledge, only one report claimed successful refolding of the bacterially
expressed recombinant LBD-LDLR in vitro by dialyzing the protein under redox
conditions (188). We made several attempts to refold the structurally similar
LBD-apoER2 under this published condition but found that this in vitro refolding
condition could not successfully refold LBD-apoER2 into its native conformation.
This problem drove us to explore other methods to refold bacterially
expressed recombinant LBD-apoER2. We found that our in vivo protein folding
technology is able to properly refold bacterially expressed apoER2 inside
mammalian cells. We further optimized this in vivo protein refolding technique
and achieved up to 20% refolding efficiency. This allows us to prepare milligram
quantity of properly refolded LBD-apoER2 that is biologically functional. This is
the main focus of this chapter.
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2.1.7. A novel in vivo protein refolding technique
Our lab recently developed a novel in vivo protein refolding approach to
efficiently refold large quantities of bacterially expressed proteins into their
properly folded and biologically functional conformations. This technique is based
on the fact that the mammalian cells have comprehensive protein folding
machinery to assist complex protein folding.
Protein folding in mammalian cells occurs in the ER, an extremely macromolecularly crowded environment harboring lots of folding enzymes and
molecular chaperones (188). Most chaperones, such as the Hsp70s, can
recognize and bind to hydrophobic residues and/or unstructured backbone
regions of non-native proteins, not only to block intermolecular aggregation but
also to prevent or reverse intramolecular misfolding. Folding enzymes, such as
disulphide isomerases and peptidyl–prolyl isomerases, can catalyze rate-limiting
steps in protein folding (12).
Not only does the ER provide a unique folding environment, but it also
exerts crucial quality control functions (188). Certain chaperones of the Hsp100
family even have the ability to unfold non-native proteins or to disrupt small
protein aggregates by an ATP-dependent mechanism. The ATP-dependent
unfolding is a prerequisite for the proteolytic degradation of misfolded proteins
(37, 38). Proteins that fail to fold or assemble are not allowed to proceed further
downstream (to the Golgi). Instead, they undergo ER-associated degradation
(ERAD).
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Figure 2-6: The technical flow chart of the novel in vivo protein refolding
technique developed by our lab.
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The target protein is first expressed in E.coli and then is subjected to affinity column
purification. The bacterial expressed protein is misfolded. The QQ-reagent modifies
the bacterial expressed protein and delivers it inside of mammalian cells for protein
refolding and post-translational modification. Properly folded protein will be purified to
obtain functional proteins.

Our refolding method takes advantage of this comprehensive protein
folding machinery inside mammalian cells by using our highly efficient QQprotein delivery technique and the high-yield bacteria expression method. As
shown in Figure 2-6, first, a very high yield of bacterially expressed proteins is
achieved by our advanced bacterial expression system. We purify bacterially
expressed recombinant proteins by affinity chromatography. If the purified
proteins are not properly folded and functional, we perform the in vivo protein
refolding procedure.

By using QQ-reagent to non-covalently modify the

bacterially expressed proteins, we deliver QQ-modified proteins to mammalian
cells for in vivo protein refolding and post-translational modification. The properly
refolded protein will be sent to its targeted intracellular compartments or will be
secreted into the cell culture medium, depending on its intrinsic signal. We then
lyse the cells or collect the culture medium to purify the properly refolded protein.
Our biophysical studies and function assay data suggest that the purified
refolded proteins adopt proper conformations and are biologically functional.
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2.2.

Material and methods

2.2.1.

Strain, plasmid and media
E.coli stain ER2556 [genotype: F − λ − fhuA2 [lon] ompT lacZ::T7 geneI

gal sulA11 ∆(mcrC-mrr)11::IS10 R(mcr-73::miniTn10)2 R(zgb-210::Tn10) 1
(TetS) endA1 [dcm]; New England Biolabs] was used for molecular cloning. E.
coli strain BL21(DE3) [F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7
gene1 ind1 Sam7 nin5; New England Biolabs] was used for protein expression
and purification. LBD-apoER2 with an N-terminal 6-histidine tag was constructed
using a pET30a-sHT bacterial expression vector which is engineered from
pET30a (+) (Novagen).

2.2.2.

DNA manipulation
The original long his-tag of the pET30a (+) vector (Novagen) was

replaced by a short his-tag containing six histidine plus two serine residues by
mutagenesis. Mutagenesis was carried out using the QuickChangeTM sitedirected mutagenesis kit (Stratagene, CA). The mutations were confirmed by
DNA sequencing.
LBD-apoER2 was subcloned into the engineered pET30a-sHT vector. The
confirmed positive DNA constructs were first transformed into E.coli ER2566
competent cells for plasmid DNA replication and glycerol stock purposes and
then were transformed into BL21(DE3) cells for protein expression.
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2.2.3.

Protein expression and purification
Protein expression was carried out using E.coli. BL21 (DE3) cells. A 10-15

ml overnight culture in a rich medium, such as 2x YT, was made from a glycerol
stock. Next morning, the overnight culture was diluted into the LB medium with a
ratio 1:100. The culture was gown in LB medium with 30 ug/ml kanamycin at 37
°C until it reached an OD 600 of 0.8-1.0. The cells were spun down and re-incubate
into a minimal M9 medium (kanamycin, 30 ug/ml) at 1:1 volume ratio. The culture
was continued at 20 °C for one hour. A sample of the cu lture was taken to check
its OD600 to confirm the continuous growth of cells under lower temperature and
the minimal M9 medium. Then expression of the recombinant LBD-apER2 was
induced by IPTG (0.5 mM, final concentration). The culture continued overnight
at 20 °C.
The cells were harvested by centrifuge next morning. The cell pellet was
re-suspended in the binding buffer (10 g/ml cells, 20 mM Tris-HCl, 500 mM NaCl,
2.5 mM imidazole, 6 M urea at pH 8.0) of His tag affinity purification system and
sonicated on ice. To separate the cell pellet from the supernatant, the cell pellet
was centrifuged. The pellet was again re-suspended in the binding buffer with 6
M urea and sonicated on ice. This procedure was repeated three times to ensure
that all bacterially expressed LBD-apoER2 in the inclusion bodies was solubilized
in the buffer system. All supernatant fractions were combined and applied on a
HisBind® resin column (Novagen). The column was washed with a large amount
of binding buffer with 6 M urea and the washing buffer containing 20-30 mM
imidazole for 100-500 ml. The purified recombinant LBD-apoER2 was eluted
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from the column using the elution buffer with 1.0 M imidazole and 6 M urea. The
eluted protein was extensively dialyzed against 10 mM ammonium bicarbonate.
After dialysis, the protein solution was lyophilized and the pure LBD-apoER2
protein powder was obtained, which was weighed and stored at -20°C for future
experiments.

2.2.4

Isotope-labeled protein expression and purification
High cell-density expression method (59) was used to greatly improve

isotope labeled protein yield at the same time to reduce the costs. The
transformed cells were inoculated into LB medium for overnight cultures, which
was then diluted by 100 volume folds into the LB medium at the next morning
and cultured at 37 °C in the presence of kanamycin (30 ug/ml). When the OD600
reached around 1.5-2.0, we switched the cell culture to isotope-labeled M9
minimal medium by gently spinning down cells and re-suspended the cell pellet
into the medium. Isotope-labeling is achieved by expressing LBD-apoER2 in this
special isotope-labeled M9 minimal medium, in which NH4Cl is replaced by 0.1%
15

NH4Cl and glucose is replaced by 0.2%

D2O for

13

C-glucose and H2O is replaced by

2

H/13C/15N triple-labeled samples, respectively. After switching the

medium, the cells were cultured for another 1.0-1.5 hours for growth recovery
and medium exchange at 37 °C. Then 0.8 mM IPTG was ad ded to induce protein
production. The cell culture was incubated in 20 °C for overnight expression. The
cells were harvested next morning. Protein purification was carried out as same
as unlabeled protein described above. The dialyzed protein solution was
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lyophilized to get the pure isotope-labeled LBD-apoER2 protein powder. The
protein powder was weighed and was stored at -20 °C fo r future experiments.

2.2.5

Cell culture
HeLa CLL-2 cells were cultured in Dulbecco minimum essential medium

(DMEM) containing 8% fetal bovine serum (FBS). The cells were maintained at
37°C in humidified air containing 5% CO 2. For protein delivery, HeLa CLL-2 cells
were incubated to reach 80% confluence (about 6x106 cells).

2.2.6.

Protein delivery time course
5 mg of bacterially expressed LBD-apoER2 was modified using 4 ml of

QQ-reagent for overnight at 4°C with gental shaking. QQ-reagent contains 15
mg/ml PEI (1300kDa) at pH8.0. Modified LBD-apoER2 was centrifuged at 5000
rpm for 5 minutes to remove precipitation. Then the modified LBD-apoER2 was
mixed with serum-free DMEM to reach the total volume of 50 ml and the final
protein concentration of 0.1 mg/ml and QQ-reagent at 1.2 mg/ml. 10 flasks (75
cm2) of 80% confluent HeLa cells were incubated with the protein delivery
medium and protease inhibitor for 10 hours. Each hour, triplicate samples of the
protein delivery medium were taken. After 10 hours of incubation with the protein
delivery medium, the protein delivery medium was removed and HeLa cells were
gently washed with PBS buffer, three times. Then fresh serum-free DMEM
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medium was added for another 12 hours. After 12 hours, samples of the medium
were taken (in triplicate). All the samples were analyzed further.

2.2.7. DNA transfection and fluorescence spectroscopy
The ER-GFP marker DNA (15 ul, 0.5 mg/ml) or Golgi-CFP marker DNA
(20 ul, 0.5 mg/ml) was mixed with Escort lipid for 2 hours (20 ul, 0.5 mg/ml). The
mixture was added into 200 ul DMEM cell culture medium and incubated for 20
minutes at room temperature. This DMEM medium was then mixed with 1 ml
DMEM containing HeLa cells and 5% FBS and incubated for 3 hrs. The cells
were washed several times and incubated in a DMEM medium with 10% FBS for
72 hours before fluorescence imaging.
The fluorescence spectroscopy was carried out using a PTI QuantaMaster
QM-7/2003 spectrofluorometer at room temperature, with an excitation at 250
nm. To deconvolute fluorescence spectra, we carried out synchronous
fluorescence spectroscopy using a program provided by PTI. In particular, the
excitation was between 250-500 nm and emission spectra were collected in both
300-550 and 500-750 nm.

2.2.8. Detect functional LBD-apoER2 in the time course media by Western
blotting and ligand-blotting assay
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2.2.8.1. Western- blotting
The recombinant LBD-apoER2 contains His-tag. Equal amount of the time
course medium samples were subjected to SDS-PAGE under reducing
conditions. Following transferring to the PVDF membrane, successive incubation
with mouse anti-His tag monoclonal antibody (Sigma) and horseradish
peroxidase (HRP)-conjugated secondary antibodies (Amersham Life Science)
were

carried

immunoreactive

out

according

proteins

to

were

the
then

manufacturer’s
detected

specifications.

using

the

The

enhanced

chemiluminescence (ECL) system.

2.2.8.2. The ligand-blotting assay
The ligand-blotting assay can detect and quantify the properly refolded
LBD-apoER2, while the bacterially expressed LBD-apoER2, which is in nonnative conformation, should give a negative signal. The working principle of the
ligand-blotting assay lies in the fact that the ligand-binding domain of apoER2 is
fully functional on nitrocellulose under a physiological relative condition. If LBDapoER2 is subjected to such procedure, the immobilized LBD-apoER2 can then
be visualized and/or quantified following incubation with ligands that can be
detected by standard Western blotting procedures.
The ligand used is the 39 kDa receptor-associated protein (RAP), which
constitutes a non-lipoprotein ligand with high-affinity (KD~1-10 nM) for the ligandbinding domain of all known members of the LDL receptor gene family (174).
RAP is a chaperone for the LDL receptor family members. It associates with the
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members of the LDLR by binding to newly synthesized and properly folded the
ligand-binding domain of the receptors, preventing premature ligand-binding
induced aggregation and subsequent degradation in the ER (125). RAP also
escorts the receptors trafficking from the ER to the Golgi apparatus. In the ligandblotting assay of LBD-apoER2, the advantage of using RAP is the high binding
affinity between RAP and folded LBD-apoER2 that it is sufficient and easy for the
detection by standard methods such as western blotting via the His tag of RAP.
And the insensitivity of RAP to detergents, but not lipoproteins, allows detergentcontaining washes to facilitate cleaner backgrounds.
Another advantage of the ligand-blotting assay is the whole procedure can
be conducted under a physiological condition and there is no denaturants to
disrupt the protein-protein interaction. Traditional far western blot assays need to
go through steps such as SDS-PAGE gel and transferring step. Fractionating
protein samples on an SDS-PAGE gel may cause the denaturation of protein
samples. Transferring protein samples from the gel onto a solid support
membrane such as PVDF or nitric cellulose membrane is assisted by the transfer
buffer, which contains denaturant methanol and a relatively high voltage. The
methanol in the transfer buffer and the heat produced while transferring may also
denature the protein. These procedures may disrupt protein-protein interaction
between the properly folded LBD-apoER2 and RAP by denaturing and produce
false-negative results. Therefore, we skip the SDS-PAGE gel running step and
the transferring step. We directly dot the PBS solution of LBD-apoER2 onto a
nitric cellulose membrane (dot blot) and incubate with the probe RAP. Then we
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apply standard Western blotting procedure to detect the bound RAP and
indirectly detect our properly refolded LBD-apoER2 in the protein samples
(Figure 2-7).

Figure 2-7: Ligand-blotting assay.

Three ul of samples was dot-blotted onto nitrocellulose membrane. After
being dried for 30 minutes, the membrane was blocked in 3% non-fat milk PBS
solution at room temperature for 1 hour with gentle agitation. For probing
purposes, a 2 mg/ml RAP PBS solution was diluted in 10 ml 3% non-fat milk PBS
solution to reach the final concentration of 20 ug/ml. After decanting the blocking
buffer, the membrane reacted with RAP for 2 hours at room temperature. The
membrane was then washed five times with 20 ml 1x PBS per 5 minutes at room
temperature. The rabbit anti-RAP (Abnova) antibody was diluted in 3% non-fat
milk PBS solution at the ration of 1:1000. The membrane was probed with rabbit
anti-RAP antibody for 1 hour at room temperature with gentle agitation. The
membrane was washed as described above. Next, the rabbit anti-RAP-antigen
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complexes were detected with goat anti-rabbit IgG (HRP-conjugate) (1:10,000),
followed by ECL detection. A replicated membrane probed with the secondary
antibody alone did not display any signals (data not shown). Represenative data
sets are shown. For presentation purposes, the squares containing each dot blot
were arranged in a single column or a row for figures although they were derived
from the same dot blot.

2.2.9.

Refolding of LBD-apoER2 inside of HeLa cells
Five mg of bacterially expressed LBD-apoER2 was modified using 4 ml of

QQ-reagent for overnight at 4 °C with gentle shaking. Modified LBD-apoER2 was
centrifuged at 5000 rpm for 5 minutes to remove precipitation. Then the modified
LBD-apoER2 was mixed with serum-free DMEM to reach the final volume and
concentration of 50 ml and 0.1 mg/ml of the LBD-apoER2 and 1.2 mg/ml of the
QQ-reagent, respectively. Ten flasks (75 cm2) of 80% confluent HeLa cells were
incubated with the protein delivery medium and protease inhibitor for 3-4 hours.
After protein delivery, the protein delivery medium was removed and HeLa cells
were gently washed three times with PBS. Then fresh serum-free DMEM
medium was added for overnight (around 12 hours). The next morning, the
overnight incubation serum-free DMEM medium, with the secreted and properly
refolded LBD-apoER2 from HeLa cells, was collected and subjected to
purification.
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2.2.10. Purification of the refolded LBD-apoER2 from Hela cells
Protein purification of the folded LBD-apoER2 secreated from the HeLa
cells was performed under native conditions without the use of denaturing
reagents such as 6 M urea. The folded LBD-apoER2A was diluted into binding
buffer that contained a high NaCl concentration (1M) to increase its solubility and
to decrease the non-specific binding of other proteins to the nickel chelating
column during purification.
The collected overnight incubation DMEM medium was 3-fold diluted with
binding buffer (20 mM Tris-HCl, 1M NaCl and 10 mM imidazole at pH 8.0) and
then loaded onto a His-bind resin column. The column was washed with another
100 ml of binding buffer followed by 100 ml of washing buffer (20 mM Tris-HCl,
1M NaCl and 20 mM imidazole at pH 8.0). The refolded LBD-apoER2 was finally
eluted using 100 mM imidazole in a 200 ml volume. The eluate was dialyzed
against 10 mM ammonium bicarbonate to remove imidazole and salts. After
extensive dialysis, the elution was lyophilized. The pure refolded LBD-apoER2
powder was weighed and stored at -20 °C.

2.2.11.

Detection of refolded LBD-apoER2 by western-blotting

The refolded LBD-apoER2 protein powder was subjected to western
blotting using an anti-His tag antibody (Sigma) and anti-apoER2 antibody
(Abnova). Equal amount of the refolded LBD-apoER2 and bacterially expressed
LBD-apoER2 were loaded onto SDS-PAGE gels. Samples were run on the gels
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under both non-reducing and reducing conditions and then transferred to PVDF
membranes; duplicate membranes were prepared. One PVDF membrane was
incubated with mouse anti-His tag monoclonal antibody and the other membrane
was incubated with mouse anti-apoER2 antibody. Both were then probed with
HRP-conjugated secondary antibodies (Amersham Life Science) according to the
manufacturer’s specification. The immunoreactive proteins were detected by
ECL.

2.2.12. Detection of the biological function of the refolded LBD-apoER2 by
the ligand-blotting assay
The refolded and the bacterially expressed LBD-apoER2 protein powder
were first dissolved in PBS buffer individually. Three ul of each were dotted onto
the nitric cellulose membrane with RAP as the positive control. After drying the
membrane for 30 minutes, the membrane was subjected to the ligand-blotting
assay (see section 2.2.8.2. for details).

2.3.

Results

2.3.1. Bacterial expression and purification of the recombinant LBDapoER2
Using our high-yield E.coli protein expression system, large amount of
recombinant LBD-apoER2 was produced. However, the recombinant LBDapoER2 includes 42 cysteines. In the E.coli protein expression systems, these
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cysteines cannot form proper disulfide bonds as seen in the native conformation
of LBD-apoER2. They randomly form non-native intramolecular or intermolecular
disulfide bonds. Most of the time, dimer, trimer or even higher oligomers were
formed. Large amount of aggregates formed inclusion bodies inside E.coli. We
used high concentrations of denaturant, such as 6 M urea, to extract the
expressed recombinant LBD-apoER2. Due to the complicated conformations of
the bacterially expressed recombinant LBD-apoER2, we normally could not
detect the expected protein band at its molecular weight of 34 kDa on a 12%
SDS-PAGE gel. Instead, we frequently detected a slower mobility protein band of
approximately 50 kDa. This protein band was found only in the whole cell lysates
of IPTG induced bacterial cells with absence of the reducing reagent, DTT
(Figure 2-8 left panel, compare lanes 1 and 2). This suggested that this slower
mobility band may be the LBD-apoER2. We performed Western blotting to
confirm that the identity of this protein band (data not shown).
The bacterially expressed LBD-apoER2 protein powder was dissolved in
PBS buffer at the concentration of 0.1 mg/ml. Unexpectedly, the band around 50
kDa seen in the whole cell lysates induced with IPTG (Figure 2-8 left panel, lane
1) was no longer detected, instead a diffuse band between 30 kDa and 40 kDa
was now observed (right panel of Figure 2-8, lane 1). Changing the buffer
condition

or

the

drying

step

(lyophilization)

could

folding/disulfide linkages, thus affecting the mobility.

have

affected

the

Though the band was

running around its expected molecular weight of 34 kDa, it does not mean the
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bacterially expressed LBD-apoER2 was properly folded. The band was diffuse,
suggesting it represents alternative folded states of the protein. Adding DTT

Figure 2-8: Expression and purification of bacterially expressed LBD-apoER2.

The left panel is the 12% SDS-PAGE stained with Coomassie blue, showing IPTG
induced expression of LBD-ApoER2 in E. coli. Whole cell lysates (without DTT)
induced with (lane 1) or without (lane 2) IPTG are shown. A protein molecular weight
marker, lane M, was loaded with the 20 and 50 kDa bands pointed out with arrows for
reference. The right panel is a Coomassie blue stained, 12% SDS-PAGE showing
the eluted fraction from nickel chelating column that contains the purified LBDApoER2. Lane 1, the eluted fraction without DTT, showing a diffuse protein band at
34 kDa. Lane 2, the eluted fraction containing 10 mM DTT. The 30, 40, and 50 kDa
bands of the molecular weight marker (lane M) are indicated for reference.
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Figure 2-9: Expression and purification of isotope-labelled, bacterially expressed
LBD-apoER2.

The left panel is the 12% SDS-PAGE showing IPTG induced expression of isotope
labeled LBD-apoER2 in the minimal medium containing

15

NH4Cl,

13

C- glucose and

D2O. Lane 1, E. coli cell lysates following induction of protein expression. Lane 2, the
E. coli cell lysates without IPTG induced expression as negative control. The right
panel is the 12% SDS-PAGE showing the purification using His•Bind column. Lane 1,
the 1st soluble fraction of inclusion bodies in 6 M urea. Lane 2, the 2nd soluble fraction
of inclusion bodies in 6 M urea. Lane 3, the flow-through of the lysates after loading
onto the nickel chelating column. Lane 4, the flow-through of binding buffer wash.
Lane 5, the flow-through of washing buffer wash. Lane 6, the eluted fraction. Lane 7,
the eluted fraction in a reaction mixture containing 10 mM DTT.

(100 mM) resulted in a single band of greater than 50 kDa (Figure 2-8, right
panel, lane 2). DTT could have released the unstable disulfied bonds (diffuse
character) in the protein and linearized the peptide chains, resulting in greatly
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reduced mobility observed (Figure 2-8, Right panel, lane 2).

We repeatedly

found this characteristic of LBD-apoER2 in the SDS-PAGEs. Therefore, this
mobility character of LBD-apoER2 with or without DTT on SDS-PAGE provided
evidence for the bacterially expressed LBD-apoER2.
The recombinant LBD-apoER2 in the inclusion bodies of E.coli was very
difficult to dissolve in the normal nickel chelating purification buffers. Six M urea
was applied throughout the whole protein purification procedure and was
removed through dialysis. A high yield of purified recombinant LBD-apoER2 was
obtained after the lyophilizing step (50 mg/liter). In order to perform NMR studies
of LBD-apoER2, we also prepared isotope labeled LBD-apoER2 (Figure 2-9).
The protein produced the same character as in the unlabled protein (compare
Figures 2-8, right panel, lanes 1 and 2 to Figure 2-9, Right panel, lanes 6 and 7).
The yield of isotope labeled protein was lower than unlabeled protein; however,
by using the high-yield protein expression system in E.coli, 60.04 mg of isotope
labeled LBD-apoER2 was obtained for further experiments.

2.3.2. Highly efficient protein delivery by QQ-reagent
To refold bacterially expressed LBD-apoER2 inside HeLa cells, we
delivered the bacterially expressed LBD-apoER2 into HeLa cells for in vivo
refolding in the ER. Using QQ-protein delivery, we can deliver different proteins.
However, due to the different biochemical properties of different proteins, an
optimization step is necessary for an individual protein for efficient protein
delivery.
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Figure 2-10: A Coomassie stained 12% SDS-PAGE showing a time course of the
QQ-protein delivery of LBD-apoER2 into HeLa cells.

Bacterially expressed LBD-apoER2 was modified using QQ-reagent at the
concentration of 0.1 mg/ml. HeLa cells were incubated with the protein delivery
medium. Aliquots of the cell culture medium were taken at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9
and 10 hours and then the protein delivery medium was exchanged for fresh serumfree DMEM medium for another 12 hours incubation. The protein samples run under
reducing conditions are shown. Lanes 1-11 were the samples from 0 to 10 hours
incubation. Lane 12, serum-free DMEM medium sample after another 12 hours
incubation. Lane 13, the bacterial expressed LBD-apoER2 served as

a positive

control and positional control for the QQ-modified protein before delievery and is
essential the same as lane 1 except that the protein in lane 13 is not modified with
QQ-reagent.
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We found that at the concentration of 0.1 mg/ml, the QQ-modified LBDapoER2 could be delivered efficiently while HeLa cells maintained their healthy
morphology.

Higher

concentrations

were

also

tried.

But

either higher

concentration of QQ-modified LBD-apoER2 or higher content of QQ reagent in
the delivery medium introduced higher cellular toxicity, causing the rapid
appearance of membrane blebs on the surface of most HeLa cells and
subsequent apoptosis (data not shown).
The QQ-modified LBD-ApoER2 was delievered into Hela cells and
samples of the cell culture medium containing both the remaining undelivered
protein as well as secreted protein was collected hourly over a 10 hour peroid.
All samples were subjected to SDS-PAGE. Under reducing conditions, focused
and sharp protein bands of LBD-apoER2 were detectable on SDS-PAGE (Figure
2-10). The results showed that the protein band (red arrow) density of QQmodified LBD-apoER2 was decreased after 3 hours (Figure 2-10, lanes 1-4),
while a new faint band of faster mobility gradually appeared in the later time
points (Figure 2-10, lanes 3-11). The slower mobility band that gradually
dissipates is the original modified protein while the faster mobility band is likely
the secreted LBD-ApoER2. After an additional 12-hour incubation with a regular
cell culture medium that did not harbor modified protein, neither band could be
detected and were likely beyond the limit of sensitivity for this method (Figure 210, lane 12).
This result demonstrated that 3 or 4 hours were the optimal protein
delivery time for LBD-apoER2, as during this time the original protein band was

87

hardly detectable (Figure 2-10, lanes 4 and 5), suggesting that it has been taken
up by the cell. This slower mobility band was replaced by the faster one at 4 hrs
and thereafter (Figure 2-10 lanes 5-11) suggesting it to be the secreted protein.
After an additional 12 hours of incuation, the secreted protein could not be
detected.
After protein delivery, the properly refolded LBD-apoER2 should be
secreted into the medium in the later time point including overnight incubation.
The LBD-apoER2 only includes the ligand-binding domain of apoER2 with the
trans-membrane domain removed. Without the transmembrane and cytosolic
domains of apoER2, this mini-receptor will be secreted into the culture medium.
We thought that the new lower faint band observed in the later time points was
the refolded LBD-apoER2.

Figure 2-11: Western-blotting to detect His-tagged LBD-apoER2 during the same
time course of QQ-delivery of LBD-apoER2.

An anti his-tag antibody was used. Lanes 1- 11 were the samples from 0 to 10 hours.
Lane 12, serum-free DMEM medium sample after another 12 hours of incubation.
Lane 13, the bacterially expressed LBD-apoER2 as a positive control. Lane 14, RAP
full length without His-tag as a negative control.
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To confirm the result of this time course, all the medium samples were
subjected to Western blotting using an anti His-tag antibody with bacterially
expressed LBD-apoER2 as a positive control and non-His-tagged RAP as a
negative control (Figure 2-11). The result showed the same pattern of QQmodified LBD-apoER2 in the delivery medium as the SDS-PAGE shown in
Figure 2-10. At 3 or 4 hours, the density of LBD-apoER2 protein bands was
sharply decreased and gradually disappeared by 10 hours after protein delivery
(Figure 2-11, lanes 4-11). However, the secreated LBD-apoER2 in the later time
points could not be detected by these Western blotting conditions (compare the
trend of the faster mobility band in Figure 2-10 to Figure 2-11). This may be due
to different conformations adopted by the refolded protein, whereby the His tag
could be buried and inaccessible to the anti His-tag antibody. Our ligand-blotting
data confirmed this suggestion (see 2.3.3). Up to this point, our data indicate that
the QQ-modified LBD-apoER2 was efficiently delivered into HeLa cells and that
the optimal LBD-apoER2 delivery time was 3 or 4 hours.

2.3.3. The LBD-apoER2 reaches to the ER after QQ-protein delivery.
Bacterially expressed LBD-apoER2 is misfolded, forming a mixture of
different oligomers (Figure 2-12, panel A, lane1), which are inactive for ligandbinding.

We

designed

specific

experiments

based

on

the

following

considerations: 1) The refolding process of LBD-apoER2 happens in the ER
(189). 2) The refolding may occur in two steps: monomer formation and refolding.
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Figure 2-12: A: A Western blot of LBD-apoER2 using a 12% SDS-PAGE and an
anti-His-tag antibody.

Lane 1: bacterial expressed LBD-apoER2 without DTT. Lane 2: the refolded LBDapoER2 from HeLa cells. Lane 3: bacterial expressed LBD-apoER2 with 20 mM DTT.
Co-localization experiments: B, fluorescence image of CFP channel (blue). C,
fluorescence image of rhodamine channel (red). D, fluorescence image of FITC
channel (green). E, Merge of the fluorescence images from all three channels with
the light microscopy image (Courtesy of Dr. Qianqian Li).

Braakman et al previously suggested that the newly synthesized
endogenous LDLR folded in a coordinated, non-vectorial pathway that included
non-native disulfide bond formation and reshuffling (189). In our case, once the
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bacterially expressed LBD-apoER2 is delivered into cells, the folding machinery
has to break up the oligomers to form a monomer for refolding. The correctly
refolded LBD-apoER2 should traffic from the ER to the Golgi, and eventually
secrete into the cell culture medium via the plasma membrane.
We transfected HeLa cells with both CFP-Golgi and GFP-ER marker
DNAs and incubated the transfected cells for 72 hours before protein delivery.
The transfected DNA labels the ER with green and the Golgi with blue
fluorescence (116).

We also labeled LBD-apoER2 with DyLight 649 and

delivered this red fluorescence labeled protein into the transfected cells. The
cells were washed and incubated in a regular cell culture medium for another 6
hours and subjected to fluorescence imaging (Figure 2-12, panel B,C,D,E).
Clearly, a merge of CFP (Panel B, Golgi location) with FITC (Panel D, ER
location) and rhodamine channels (Panel C, LBD-apoER2 intracellular location)
shows merging fluorescence (Panel E), demonstrating that the delivered LBDapoER2 is in the ER and Golgi for refolding.

2.3.4.

Optimizing the in vivo protein refolding protocol for LBD-apoER2

Our time course data suggested that the bacterially expressed LBDapoER2 was efficiently delivered into the HeLa cells. The delivered, bacterially
expressed LBD-apoER2 should be inside the ER for refolding, which takes time.
The properly refolded LBD-apoER2 should follow the secretary pathway for
secretion into the serum-free medium, while the persistent unfolded LBD-apoER2
would be degraded by the ERAD, since the transmembrane domain of LBD-
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apoER2 was removed. This raised an important question as to when was the
best time point to re-purify the properly refolded LBD-apoER2 from the cell
culture medium for the highest yield of refolding.

Figure 2-13: Ligand-blotting assay to detect RAP binding to the functional LBDapoER2 after refolding.

Three ul of the medium were spotted onto a nitrocellulose membrane. The blot was
incubated with 20 ug/ml full-length RAP after blocking. The bound RAP was probed
by rabbit anti-RAP antibody followed by goat anti-rabbit IgG. Lanes 1-11 were the
time points of 0 to 10 hours. Lane 12, serum-free DMEM medium sample after
another 12 hours incubation. Lane 13, 0.1 mg/ml bacterial expressed LBD-apoER2
as a negative control. Lane 14, RAP full-length as a positive control.

We addressed this question using a ligand-blotting assay with these time
course samples. Ligand-blotting can be used to specifically detect properly folded
LBD-apoER2 due to its binding to RAP. While the bacterially expressed LBDapoER2 is delivered into HeLa cells, their protein folding machinery will try to
refold the delivered LBD-apoER2, and the properly refolded protein will be
secreted from the cells. This is a continuous process. Our ligand-blotting assay
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result (Figure 2-13) showed that the refolded LBD-apoER2 was indeed secreted
into the medium and gradually accumulated in the medium. At 0-3 hours, nearly
no positive dot-blot signals were observed (lanes 1-4), which was confirmed by
the negative control of Lane 13, the bacterially expressed LBD-apoER without in
vivo refolding. As time proceeded, significant intensity of the dot-blot signals were
observed at 4-7 hours (lanes 5-8). At 8-hours, the strongest signal was observed
which was maintained all the way to 10-hours (lanes 9-11). In addition, strong
dot-blot signals were also observed in the medium of another overnight cell
culture (lane 12). This data indicated that the cell culture medium during this time
course contained the secreted and properly refolded LBD-apoER2 and the
refolded LBD-apoER2 reached the highest concentration at 8-hour after QQdelivery. In addition, the amount of the refolded protein was continuously
accumulated in the cell culture medium during an overnight cell culture with QQprotein delivery.
Although the refolded LBD-apoER2 could not be detected in the
Coomassie stained gel after an additional overnight incubation (Figure 2-10 lane
12), the dot blot clearly demonstrated that the refolded protein was indeed
present in the overnight medium (Figure 2-13, lane 12).

As the overnight

medium did not harbor any QQ-modified protein, coupled with the lack of signal
from the undelivered bacterially expressed protein (Figure 2-13, lane 13), the
similar trend between the fast mobility band (Figure 2-10, lanes 3-11) and the
RAP dot blot (Figure 2-13) strongly argue that the faster mobility band observed
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(Figure 2-10) is likely the functional and refolded LBD-apoER2, being responsible
for the RAP binding (Figure 2-13).
We quantified the ligand-blotting data using the Kodak 1D image analysis
software. As shown in Figure 2-14, the amount of the refolded LBD-apoER2 kept
increasing until the 8 hours time point where it reached its peak. After 8 hours,
the amount of the refolded LBD-apoER2 in the incubation medium remained
constant.

Figure 2-14: The bar graph of signals quantified from the ligand-blotting assay
(Figure 2-13), showing the accumulation of the secreted and refolded LBD-apoER2
in the serum-free medium.
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Since this in vivo refolding is a complicated process, containing protein
refolding, ERAD degradation of consistently misfolded protein, and secretion of
the folded protein, it is difficult to identify the best timing to obtain the highest
yield of the refolded protein. However, our data clearly indicated that the
secretion of the refolded LBD-apoER2 peaked at 8 hours after protein delivery.
Eight to 10 hours incubation time for in vivo refolding was the optimal condition.

2.3.5. Refolded LBD-apoER2 was secreted into culture medium.
For LBD-apoER2 in vivo refolding, our optimal experimental condition
was 4-hour QQ-protein delivery, followed by an additional 8-10 hours for protein
refolding and secretion (Figure 2-15). Under this condition, most bacterial
recombinant LBD-apoER2 was delivered inside HeLa cells by the QQ-protein
delivery. The delivered LBD-apoER2 was refolded by the ER refolding machinery
and most refolded LBD-apoER2 was secreted into the cell culture medium. We
focused on cell culture medium to take advantage of the secreted LBD-apoER2
since it should be properly refolded and relatively more pure as compared to the
LBD-apoER2 inside HeLa cells that might contain mixed population of refolded
and misfolded LBD-apoER2.
To confirm this, medium samples at different time points were taken
during protein refolding, and HeLa cells were also lysed afterwards. All samples
were subjected to a SDS-PAGE with or without DTT. HeLa cells were also
incubated with the protein delivery medium that only contained QQ-reagent
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Figure 2-15: 12% SDS-PAGEs, showing the in vivo protein refolding.

HeLa cells were incubated with the protein delivery medium for 4 hours. The protein
delivery medium was exchanged to fresh serum-free DMEM medium without QQLBD-apoER2 and cultured for another 10 hours. The samples were subjected to
SDS-PAGE analyses without (left) and with (right) DTT. Lane 1, the HeLa cell lysates
after 4-hour protein delivery and 10-hour protein refolding. Lane 2, the control HeLa
cell lysates without protein-delivery. Lane 3, the protein delivery medium with 0.1
mg/ml bacterial expressed LBD-ApoER2 before adding HeLa cells. Lane 4, the
protein delivery medium after 4 hours post protein delivery. Lane 5, the culture
medium after 10 hours of protein refolding. Lane 6, the cell culture medium with QQreagent without adding HeLa cells as a negative control. Lane 7, the control HeLa cell
culture medium with the QQ-reagent only after 4 hour culture. Lane 8, the serum-free
DMEM medium after another 10 hour with the control HeLa cells. The blue arrow
head indicates a secretion protein from HeLa cells. The faint yet properly refolded
LBD-ApoER2 band that is secreated into the medium is noted by a red arrow.

96

under the same experimental condition. The cell culture medium of this control
experiment were also taken as a negative control.
Consistent with our previous data, LBD-apoER2 was not detectable in the
HeLa cell lysates (lane 1) and was only detectable in the cell culture medium
(lane 5) (Figure 2-15). This result confirmed the suggestion that protein refolding
did not lead to the accumulation of the LBD-apoER2 inside HeLa cells. Instead,
the properly refolded LBD-apoER2 was secreted into the cell culture medium. In
addition, our data indicated that the QQ-protein delivery method efficiently sent
the LBD-apoER2 inside HeLa cells since the LBD-apoER2 band intensity was
significantly decreased (lane 4). Accordingly, Lane 5 showed detectable refolded
LBD-apoER2 after 10-hour cell culture (red arrow). The higher molecular weight
bands shown on the gels (lanes 4, 5, 7, and 8, Blue Arrow Head) came from a
HeLa cell secretary protein, which persistently existed in the medium during in
vivo protein refolding. This result was confirmed by the negative controls on the
SDS-PAGE gels (lanes 6-8).

2.3.6.

The yield of refolded LBD-apoER2
The incubation medium (serum-free) was collected after refolding and

the properly refolded LBD-apoER2 was subjected to protein purification using the
nickel chelating column. Our results showed that the biochemical properties of
the properly folded LBD-apoER2 were different from the bacterially expressed
protein. The solubility of the folded LBD-apoER2 was lower and the binding
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capability to the nickel chelating column was decreased. This is consistent with
the possibility that the his-tag may be partially occluded in the refolded protein
and could be responsible for the lack of signal in the Western (Figure 2-11) and
the decreased binding observed despite the his-tag being present. This forced
us to optimize the purification protocol for the refolded LBD-apoER2. Three main
modifications were carried out: (1) the volume of purification buffer was increased
to reduce the refolded LBD-apoER2 concentration and to decrease potential
possibility of precipitation; (2) high concentrations of NaCl in the purification
buffer were included in order to avoid non-specific protein binding to the His•Bind
column and to increase the solubility of the refolded LBD-apoER2; (3) decreased
concentrations of imidazole in the elution buffer because we found that high
concentrations
precipitation

of

of

imidazole

the

refolded

would

cause

LBD-apoER2

irreversible
during

aggregation

dialysis.

The

and
lower

concentration of imidazole was sufficient to elute the refolded protein due to the
weaker interaction with the column resin.
Even though we optimized protein delivery, protein refolding, and protein
purification conditions throughout this in vivo protein refolding technique for LBDapoER2, the final yield of the purified refolded LBD-apoER2 remained low. We
obtained a yield less than 10% of the refolded LBD-apoER2 compared to the
imput amount (QQ modified, bacterially expressed protein used for delivery) as
shown in Table 2-1.
This is not surprising since LBD-apoER2 contain 21 disulfide bonds and
7 Ca2+-binding sites. The folding of this protein is challenging. It has been
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demonstrated by others that only 30% of the newly synthesized LDLR was
properly folded and the rest proteins were degraded by ERAD due to misfolding
(189). Our data confirmed this result for our refolding, since we could only
recover less than 10% of the bacterially expressed LBD-apoER2 (Table 2-1).
This suggested that most of the QQ-delivered LBD-apoER2 was degraded due to
the limits of the ER folding capability. We re-purified the bacterially expressed
LBD-apoER2 from the protein delivery medium after 4 hours of delivery. The repurified bacterially expressed LBD-apoER2 protein could be re-used in the next
round of in vivo protein refolding experiments to increase the refolding efficiency.
Those consistently misfolded LBD-apoER2 were subjected to ERAD degradation
due to ER quality control system. Another possible reason for this low yield was
the purification due to the reduced affinity of the refolded LBD-apoER2 for the
His-tag resin. After refolding, LBD-apoER2 underwent conformation changes that
might make the his-tag buried and not available to bind to his-tag resin, causing a
low yield of the refolded LBD-apoER2.
Table 2-1: Three representative yields of refolded LBD-apoER2.
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2.3.7.

The refolded LBD-apoER2 is biologically functional
To further confirm the purified refolded LBD-apoER2 powder is properly

folded and biologically functional, we dissolved the protein powder in PBS buffer
with 1 mM CaCl2 and performed Western blot and ligand blotting. As shown in
Figure 2-16 A-C, with (lanes 3 and 4) or without reducing reagent DTT (lanes 1
and 2), the refolded LBD-apoER2 (lanes 1 and 3) showed the same mobility as
the bacterially expressed one (lanes 2 and 4) on the 12% SDS-PAGE gel (Panel
A). Western blotting (Panel B and C) showed positive signals for the refolded
LBD-apoER2 as well as the bacterially expressed one, identifying the protein
powder was LBD-apoER2. Interestingly, the LBD-ApoER2 antibody only
recognized the protein when it was under reducing conditions (panel B, lanes 3
and 4) suggesting that the epitope is hidden in the refolded (lane 1) or misfolded
proteins (lane 2). However, the His tag remained accessible as its was detected
in all lanes (panel C).

Likely, the properly refolded LBD-ApoER2 was not

detected in Figure 2-11 due to its trace amount but was clearly detected here
(Figure 2-16, panel C). Ligand-blotting assay (panel D) of the refolded LBDapoER2 protein powder showed a positive signal, similar to the RAP dot-blot as
the positive control. However, the bacterially expressed LBD-apoER2 protein
powder showed a negative signal. This result confirmed that the refolded LBDApoER2 powder displayed a proper conformation that bound to RAP. Thus, the
refolded LBD-apoER2 protein powder is biologically functional unlike the
bacterially expressed one.
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Figure 2-16: SDS-PAGE, Western blots using anti-apoER2 and anti his-tag
antibodies and ligand blotting of the refolded LBD-apoER2 protein powder.

Panel A: a 12% SDS-PAGE stained with Coomassie blue. Panel B: A Western blot
using anti-apoER2 antibody. Panel C: A Western blot using anti His tag antibody. In
all three panels, Lane 1, the refolded LBD-apoER2 powder. Lane 2, bacterial LBDapoER2 powder. Lane 3, bacterial LBD-apoER2 powder with 10 mM DTT. Lane 4,
the refolded LBD-apoER2 powder with 10 mM DTT. Panel D: Ligand-blotting to
detect the binding of RAP to the functional LBD-apoER2. The bound RAP was
probed by anti-RAP antibody.
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2.4.

Discussion
Proteins have to adopt the correct three-dimensional structures in order

to be functional. Obtaining the native fold of a protein sometimes is not a simple
task, especially when the protein is expressed in E. coli to meet the need of large
quantity of properly folded proteins for structural study or for therapeutics. Many
proteins precipitate in the form of inclusion bodies when synthesized in E. coli. In
vitro experimental approaches have been developed to refold the aggregated
proteins into their biologically active forms. The main refolding strategies are
chromatographic methods and refolding in free solution. New techniques
employing additives that aid in protein refolding, such as chaperone proteins,
may become more widely used. However, these new methods require rigorous
testing for refolding of not only simple model proteins such as RNase A, but also
for proteins with complex folding.

New techniques of protein refolding are

needed to increase the robustness of refolding processes and to decrease the
costs for broader applications.
Our lab recently developed a novel in vivo protein refolding technique.
Different from other in vitro protein refolding techniques, this protein refolding
technique enables protein refolding inside of mammalian cells and is facilitated
by folding chaperones and enzymes in the ER and the Golgi. The ER quality
control system ensures that only properly refolded proteins continue intracellular
trafficking whereas the persistent unfolded protein is degraded by ERAD or UPR
(Figure 1-2 and 1-3). Properly folded and biologically functional proteins follow
the same intracellular trafficking pathway as endogenous ones. Additionally, the
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refolded protein can be purified from mammalian cells or the culture medium
depending on the design and properties of the refolded proteins.
This in vivo protein refolding technique is based on a highly efficient
recombinant protein expression method in E. coli and the QQ-protein delivery
technique, which were recently developed in our lab. Specially, the unique QQreagent can non-covalently attach to the bacterially expressed proteins, protect
the proteins from degradation, and efficiently deliver them inside of mammalian
cells. The delivered proteins traffic to the ER and Golgi and undergo efficiently
protein refolding by the ER folding machinery. Thus, this in vivo protein refolding
technique utilizes ER protein folding machinery and quality control system to
efficiently refold proteins and to ensure that the misfolded proteins will be
degraded, thus, providing a novel protein refolding technique that is currently
unavailable for the scientific community.
ApoER2 is one of the primary members of LDL receptor family, playing
an important role in lipid metabolism in the brain and neurodegenerative
diseases such as Alzheimer’s disease. Like its homologue - LDL receptor,
apoER2 has five major motifs: complement-like binding repeats/the LDL receptor
type-A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats, a
transmembrane domain and a short cytoplasmic tail (Figure 2-1). Studies
showed that the seven complement-like repeats form a ligand-binding domain,
mainly responsible for binding to the ligands such as apoE, RAP and Reelin
(161, 174, 190). Even though no structural information of apoER2 has been
reported, structure studies on other LDL receptor family members like LDL
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receptor and LRPs have shown that the each ligand binding repeat in the ligandbinding domain contains six cysteines, forming three disulfide bonds per repeat
(190). The negatively charged amino acids (Asp/Glu) at the C-terminus of each
repeats are considered to be important for the ligand binding function, partially
complementary to the positively charged residues on apoE or RAP (190). Also,
these acidic residues form an important calcium coordination site, which is highly
conserved. Calcium was reported to be important for receptor folding, stabilizing
the secondary structure and ligand binding (191). Thus, the ligand-binding
domain of LDLR family has a complex folding and refolding of this complex
structure is very challenging.
We undertook this challenge and explored efficient refolding of the
human LBD-apoER2 using this in vivo protein refolding technology. We believe
that this is one of the ultimate measures for this in vivo protein refolding
technology and the successful refolding of LBD-apoER2 will be a good testimony
of the enabling capability of this technology. We subcloned the ligand-binding
domain of apoER2 (LBD-apoER2) into a high-level expression vector which was
expressed in E. coli using our high cell-density expression method to produce
gram quantity pure recombinant LBD-apoER2 (59). We then optimized the in vivo
protein refolding conditions specific for the efficient refolding of LBD-apoER2. We
showed that QQ-modified bacterially expressed LBD-apoER2 could be efficiently
delivered inside HeLa cells in 3 to 4 hours at 0.1 mg/ml concentration (Figures 210). Once the delivered LBD-apoER2 reaches the ER (Figure 2-12), the protein
folding process begins. The bacterially expressed LBD-apoER2 undergoes
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protein refolding process, which is facilitated by chaperones and folding enzymes
in the ER. The quality of refolded protein is monitored by the QC system in the
ER. Persistent unfolded LBD-apoER2 is degraded by ERAD or UPR. The
properly folded LBD-apoER2 follows

the

same secretary

pathway as

endogenous counterpart and is secreted into the cell culture medium if it is a
secretion protein.
Because LBD-apoER2 only includes the ligand-binding domain with the
transmembrane and cytosolic domains removed, this mini-receptor will not locate
on the cell membrane as the full-length apoER2. Instead, LBD-apoER2 will be
secreted into the culture medium once they are properly refolded. Our data of a
time course of refolding indicated that the refolded LBD-apoER2 was gradually
accumulated in the culture medium with the peak of accumulation at 8-10-hours
after protein delivery. After reaching the peak, the level of the refolded LBDApoER2 in the medium remained the same during this 10-hour time course.
Thus, our data suggested that the refolding of the QQ-delivered LBD-apoER2
might be nearly completed by the ER folding machinery under our experimental
condition. This allowed us to optimize the in vivo protein refolding protocol for
LBD-apoER2 by QQ-protein delivery for 4-hours, followed by additional 8-10hours of protein refolding in the regular cell culture medium for the best yield of
the refolded LBD-apoER2.
Purification of the refolded LBD-apoER2 from the cell culture medium
turned out to be a challenging task since the refolded LBD-apoER2 seemed to
significantly reduce its binding capability to His-tag resin, thus causing a major
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trouble to purify them. However, this is one of the key steps for the final yield of
the refolded LBD-apoER2 protein. We had to optimize our standard purification
protocol by increasing the sample loading volume and NaCl concentration in the
loading and washing medium and reducing the imidazole concentration in the
elution buffer. These modifications greatly improved binding capability of the
refolded LBD-apoER2 to His tag resin that significantly enhanced the purity and
yield of the refolded LBD-apoER2.
We probed the function of the refolded LBD-apoER2 by a ligand-blotting
assay using RAP as the ligand and an anti-RAP antibody. RAP acts as a
specialized chaperone inside the ER and binds to properly folded and functional
ligand-binding domains of the LDLR family including apoER2 with nM binding
affinity (174). No denaturing reagents or detergents were used in this ligandblotting assay. However, 1 mM calcium ion was added since calcium was critical
for RAP-binding to LBD-apoER2. The pH was adjusted to 7.2 to mimic the pH
inside the ER. Our data clearly demonstrated that the properly refolded LBDApoER2 was biologically active for RAP binding, confirming the efficiency of this
novel in vivo protein refolding technology.
This in vivo protein refolding technique is unique compared to the other
in vitro protein refolding techniques. It takes advantage of the efficiency of the ER
folding machinery of mammalian cells. By providing a physiological environment,
the bacterially expressed misfolded LBD-apoER2 was efficiently refolded by the
ER folding chaperones and enzymes. In addition, the refolding quality of LBDapoER2 is closely monitored by the quality control system in the ER. Only the

106

properly refolded protein can be further subjected to post-translational
modifications and eventually secreted into cell culture medium. In contrast, the
persistent unfolded LBD-apoER2 is degraded by ER-associated degradation or
unfolded protein response mechanism in the ER.
This was confirmed by the previous data of my colleague Dr. Qianqian Li,
who delivered the bacterially expressed MESD inside mammalian cells (data not
shown). After purification, she found two major glycosylation forms of MESD in
addition to the native MESD protein. The glycosylation patterns were the same
as those of the endogenous MESD. This is an important achievement since
properly posttranslationally modified and refolded proteins are important to the
biological activity of a protein, which is especially critical towards the production
of therapeutic proteins for human disease therapies. Our results suggest that we
have successfully achieved this goal for refolding of LBD-apoER2.
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Chapter III
Refolding of the beta-propeller/epidermal growth factor-like (EGF) domain I
of low-density lipoprotein (LDL) receptor-related protein 6 (BP1-LRP6)
inside of mammalian cells

3.1.

Introduction

3.1.1.

LRP5/6 are members of the low-density lipoprotein receptor (LDLR)
family with unique structural arrangements
The LDLR family contains more than 14 members of cell surface

receptors. Although the members in this family performs diverse functions, they
share common structural domains: 1) ligand-binding domain of the complementtype (CR)repeats, 2) epidermal growth factor (EGF) -like repeats, 3) YWTD
(Tyr−Trp−Thr−Asp) β-propeller domains, 4) a transmembrane domain, and 5)
one or more endocytic motifs within their cytoplasmic domains (Figure 2-1) (192).
LDL receptor-related protein 5 (LRP5) and LRP6 are structurally diverse from the
other LDLR family members. Rather than having large clusters of ligand binding
CR repeats in the extracellular region, LRP5/6 contain only three ligand binding
CR repeats that are next to the transmembrane region (Figure 2-1). Instead, the
YWTD β-propeller/EGF (BP) modules occupy most of the extracellular domain
and play important functional roles. Ligands of other LDLR members typically
bind to clusters of ligand-binding CR repeats, whereas all identified ligands for
LRP5/6 bind to the YWTD β-propeller/EGF (BP) modules (192). Evidence
implicating YWTD domains in protein−protein interactions has emerged from
several studies. LRP6 from xenopus along with its homologs in mice and the fly
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(Drosophila) binds to the developmental signaling protein Wnt, implicated as a
co-receptor in Wnt signaling (141-143).
The LDLR family members play important roles in diverse physiologic
progresses, including lipoprotein metabolism, protease regulation, calcium
homeostasis, cell migration, and embryonic development (193). For example,
VLDLR and ApoER2 mediate Reelin signaling in neuronal cell migration during
embryonic development (140), and LRP1 participates in PDGF-mediated
signaling (194). However, LRP5 and 6 were identified as indispensible coreceptors of the canonical Wnt/β-caternin pathway and function primarily in Wnt
signaling pathway (141, 142).

3.1.2. LRP5/6 are essential receptors for the canonical Wnt signaling
pathway
The discovery of the common evolutionary origin of the Drosophila
segment polarity gene Wingless and the murine proto-oncogene Int-1 laid the
foundation for the canonical Wnt signaling pathway (195). The name Wnt was
coined as a combination of Wg (Wingless) and Int. The Wnt signaling pathway
plays a critical role in orchestrating proper tissue development in embryos and
tissue maintenance in adults (196-198). It has been shown that Wnt activates at
least three intracellular signaling pathways including the Wnt/β-catenin (canonical
Wnt pathway), planar cell polarity (PCP), and Ca2+pathway (Figure 3-1) (199). In
the PCP pathway, Wnt activates small G protein including Rho and Rac through
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Dishevelled (Dsh), thereby activating Rho-associated kinase (ROCK) and JNK
(200). The PCP pathway is involved in the regulation of tissue polarity, cell
migration, and cytoskeletal arrangement. Furthermore, Wnt increases the
intracellular Ca2+ concentration probably by activating protein kinase C (PKC)
and Ca2+/calmodulin-dependent protein kinase. The Wnt/Ca2+ pathway regulates
cell adhesion and cell movement during gastrulation (201).
The canonical Wnt pathway, which regulates the ability of the β-catenin
protein to drive activation of specific target genes, is better characterized. In the
absence of a Wnt signal, β-catenin is actively degraded in the cell by the actions
of a multiple-protein complex called the “destruction complex”. Within the
complex the Axin and adenomatous polyposis coli (APC) form a scaffold that
facilitates β-catenin phosphorylation by casein-kinase I α (CK1 α) and glycogen
synthase kinase (GSK3 β). The phosphorylated β-catenin is subsequently
recognized and ubiquitinylated, resulting in its proteasomal degradation (Figure
3-2) (202). However, in the presence of Wnt signals, β-catenin can be
accumulated and be translocated to the nucleus, where it interacts with the T-cell
factor/lymphoid enhancing factor (TCF/LEF) family of transcription factors,
leading to the transcription of Wnt target genes (202). The Wnt/ β-catenin
signaling pathway directs a specific set of genes that strictly control temporal and
special regulation of cell proliferation, differentiation, survival, and movements
(197, 198). Therefore, aberrant activation of this pathway can lead to tumor
formation.
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Figure 3-1: A schematic representation of the Wnt signal transduction cascade
(199).

(b) For non-canonical or planar cell polarity (PCP) signaling, Wnt signaling is
transduced through Frizzled independent of LPR5/6. Utilizing the PDZ and DEP
domains of Dsh, this pathway mediates cytoskeletal changes through activation of the
small GTPases Rho and Rac. (c) For the Wnt-Ca2+ pathway, Wnt signaling via
Frizzled mediates activation of heterotrimeric G-proteins, which engage Dsh,
phospholipase C (PLC; not shown), calcium-calmodulin kinase 2 (CamK2), and
protein kinase C (PKC). This pathway also uses the PDZ and DEP domains of Dsh to
modulate cell adhesion and motility. Note that for the PCP and Ca2+ pathways Dsh is
proposed to function at the membrane, whereas for canonical signaling Dsh has been
proposed to function in the cytoplasm
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LRP5 and LRP6 exhibit overlapping, as well as distinct, tissue- and celltype-specific expression patterns (192, 203). Mice deficient in Lrp6 gene are
embryonic lethal; the mutant embryos exhibit developmental defects that
resemble the phenotypes observed for individual Wnt ligand mutants, including
mid/hindbrain defects, posterior truncation, and abnormal limb patterning (141).
In contrast, LRP5 knock out (KO) mice are viable and fertile, although they
exhibit low bone mass and eye vascularization defects (152). Interestingly, it has
been shown that overexpression of LRP6 confers significantly stronger Wnt
signaling activity than LRP5 in Xenopus and mammalian cells (142, 192). Thus, it
is possible that LRP5 and LRP6 exhibit functional redundancy, most likely by
acting with different efficiencies in a context-dependent manner. The features of
LRP5-KO mice recapitulate human osteoporosis-pseudoglioma syndrome,
whereas gain-of-function mutations in Lrp5 affects the homeostatic balance of
osteoblasts and osteoclasts after birth, which leads to high bone mass (152,
204). Recently, LRP6 mutations and polymorphisms were found to be associated
with various human diseases, including coronary artery disease, Alzheimer’s
disease, hyperlipidemia, and osteoporosis (192, 205). These studies indicate a
possible predominant role of LRP5 in bone development and maintenance and a
broader role of LRP6 in pathophysiology.

112

Figure 3-2: A simplified classical view of Wnt/β-catenin signaling (192).

(A) Without Wnt, the scaffolding protein Axin assembles a protein complex that
contains Apc, Gsk3, Ck1, and β-catenin. In this complex, β-catenin is sequentially
phosphorylated by Ck1 and Gsk3. Phosphorylated β-catenin is recognized by β-Trcp,
which is a component of an ubiquitin-ligase complex that conjugates β-catenin with
ubiquitin. Poly-ubiquitinated β-catenin is degraded by the proteosome. TCF/LEFassociated co-repressors, such as Groucho, and Axin-associated Diversin, PP2A and
other proteins are omitted for simplicity. (B) In the presence of Wnt, β-catenin
phosphorylation and degradation is inhibited. Accumulated β-catenin forms a nuclear
complex with the DNA-bound TCF/LEF transcription factor, and together they activate
Wnt-responsive genes. This signaling cascade is perhaps initiated by a Wnt-induced
Fz-Lrp5/Lrp6 co-receptor complex, which recruits Axin to the plasma membrane
through Lrp5/Lrp6-Axin association. Fz-associated Dishevelled (Dvl) protein may bind
Axin and inhibit Axin-Gsk3 phosphorylation of β-catenin, either directly or indirectly
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via Dvl-associated proteins. Lrp5/Lrp6-Axin binding may also promote Axin
degradation. Either or both of these events can lead to β-catenin accumulation. This
description represents one of several possibilities. The composition of the Axin
complex upon Wnt stimulation is not well defined. Gsk3-binding protein (GBP/Frat),
and nuclear β-catenin-associated Legless/Bcl9 and Pygopus are omitted for
simplicity.

3.1.3. The YWTD β-propeller/EGF (BP) domain of LDL receptors and the
molecular chaperone MESD
The number and arrangement of different LDLR domains varies greatly
among different members of LDLR family; in humans, sizes range 5-fold from the
smallest LDLR (95 kDa) to the largest LRP2 (522 kDa) (206, 207). Such large
and complex proteins challenge structural studies. However, a crystal structure of
LDL receptor YWTD β-propeller/EGF (BP) domain was solved as shown in
Figure 3-3.
The YWTD repeat is folded into a six-bladed β-propeller domain. Each βpropeller consists of six blades arranged radially about a central axis (Figure 33). Along this axis is a central channel, 8−9 Å in diameter, filled with water
molecules that form hydrogen bonds with backbone and side chain from the βstrands lining the channel. Each blade of the propeller has four antiparallel βstrands that are offset from the YWTD repeats. The “first” strand of the sixth
blade is a C-terminal strand that follows the fifth blade to complete circularization
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of the steroidal YWTD β propeller domain. The YWTD β propeller is followed by
an EGF-like domain (E3) that packs against the propeller to create a continuous
hydrophobic core in the mature protein (130). The linker connecting the propeller
to E3 packs tightly against the base of the propeller and contacts predominantly
hydrophobic side chains in the 1−2 loops of blades two and three, situating E3 in
contact with the second and third blades of the propeller. The large interface area
between the YWTD domain and the C-terminal EGF modulesuggest that other
members of the LDLR family will share this organization, including the BP
domain of LRP-6.

Figure 3-3: Ribbon representation of the YWTD domain and adjacent Cterminal EGF-like module (E3) of the LDL receptor, colored to point out the
six YWTD repeats of the six-bladed propeller (130).

For LDLR and LRPs, at least two private chaperones, the LRP-receptorassociated protein (RAP) and the Boca/Mesd chaperone, are dedicated to the
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folding and maturation of these multi-domain proteins as they transit through the
secreatory pathway to the cell surface (114, 115). RAP binds the cysteine-rich
ligand-binding modules of LDLR family members, preventing premature
association with their respective ligands. Also, RAP escorts fully folded LDLR
family members from the ER to the Golgi, where the lower pH triggers RAP to
dissociate and recycle back to the ER via its retention signal (126). In Drosophila,
Boca was shown to promote maturation and surface expression of several LDLR
family members through a direct, but transient, interaction (114, 187). Boca/Mesd
family members are localized in the ER, where they aid in the folding of YWTD βpropeller domains. ER chaperone proteins provide the most prevalent
mechanism for achieving quality control during protein translation and
translocation (208). Boca/MESD are important for the folding of LRP5 and LRP6,.
Our lab recently solved the high resolution NMR structure of full-length of
MESD (209).

MESD contains two structural and functional domains: a

chaperone domain and an escort domain. The chaperone domain is located in
residues 1-150 and highly structured, with a four-stranded anti-parallel β-sheet in
the center, surrounded by two rigid helices on the top and one rigid helix in the
bottom. Another flexible short helix is also above the sheet, containing several
critical binding-residues to the BP domain of LRP6. The escort domain is located
in residues 151-195 and is flexible, containing two short helices and an array of
conserved lysine and arginine residues.
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3.1.4. Challenge of refolding of BP1-LRP6
The BP1-LRP6 is a 328-amino acid fragment at the N-terminal of LRP6,
including six YWTD β-propeller motifs and one epidermal growth factor (EGF)like repeat. It is a multiple domains protein with three disulfide bonds in the EGF
domain. Refolding such a complex multiple-domain protein BP1-LRP6 in vitro is
challenging. Spontaneous refolding in vitro is only efficient for small, singledomain proteins that fold rapidly. multiple domain proteins often refold
inefficiently due to the formation of partially folded intermediates that tend to selfassociate (aggregate) into disordered complexes, driven by hydrophobic forces
and inter-chain hydrogen bonding. The aggregation process irreversibly removes
proteins from their productive folding pathways and only can be avoided in vivo
protein refolding facilitated by molecular chaperones.
Previous in vitro protein folding studies with BP1-LRP6 have shown that
not only the formation of disulfide bonds in vitro occurs significantly slower than
in vivo, but also the efficiency of forming native disulfide bonds in vitro is
dramatically lower than in vivo, even under the most favorable condition (210).
During in vitro refolding, non-native disulfide bonds may be formed. Compared
with the lower efficiency of forming native disulfide bonds in vitro, our in vivo
protein refolding technique can offer much greater native disulfide bond formation
efficiency.
Specific ER chaperone MESD was reported to be necessary for the
folding of BP1-LRP6 (211). Our in vivo protein refolding technique can equip the
refolding process with complete molecular chaperones and folding enzymes,
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greatly increasing the refolding efficiency. Therefore, to refold large quantities of
bacterially expressed BP1-LRP6 into its native conformation, we used our novel
in vivo protein folding technology.

3.2.

Material and methods

3.2.1.

Strain, plasmid and media
E. coli cells were grown in Luria-Bertani (LB) medium (BD) at 37℃ and

then were grown in minimal M9 medium at 20℃ for overnight. Kanamycin (30
µg/ml) was added as required. E. coli stain ER2556 [genotype: F − λ − fhuA2 [lon]
ompT lacZ::T7 geneI gal sulA11 ∆(mcrC-mrr)11::IS10 R(mcr-73::miniTn10)2
R(zgb-210::Tn10) 1 (TetS) endA1 [dcm]; New England Biolabs] was used for
molecular cloning. E. coli strain BL21(DE3) [F- ompT hsdSB (rB-mB-) gal dcm
(DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5; New England Biolabs] was used for
protein expression and purification. BP1-LRP6 with an N-terminal 6-histidine tag
was expressed from plasmid pET30a (+) (Novagen).

3.2.2. DNA manipulation
The original long his-tag of the pET30a (+) vector (Novagen) was replaced
by a short His tag containing six histidine plus two serine residues by
mutagenesis. Mutagenesis was carried out using the QuickChangeTM site-
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directed mutagenesis kit (Stratagene, CA). The mutations were confirmed by
DNA sequencing.
Human BP1-LRP6 cDNA (kindly provided by Dr. Guojun Bu, Mayo Clinic,
Jacksonville, FL, USA) was used as the template of PCR. BP1-LRP6 was
constructed by subcloning PCR products into the BamHI/XbaI sites of the
engineered pET30a(+) vector. BP1-BP1-LRP6 includes six YWTD β-propellers
and one EGF repeat, referring the residues 20-324 of full-length LRP6. The
constructs derived from PCR were confirmed by DNA sequencing.
The engineered pET30a (+) vector provide high protein expression level.
The confirmed positive DNA constructs were first transformed into the E. coli
strain ER2566 competent cells for plasmid DNA replication and glycerol stock
production. Ultimately, they were transformed into BL21 (DE3) cells for protein
expression.

3.2.3. Protein expression and purification
Protein expression was carried out using the E. coli strain BL21(DE3). A
10-15 ml overnight culture in a rich medium, such as 2×YT, was made from a
glycerol stock of BP1-LRP6 expressing cells. The next morning, the overnight
culture was diluted into the LB medium with a ratio 1:100. The culture was grown
in LB medium with 30 ug/ml kanamycin at 37 °C until it reached an OD600 of 0.81.0. The cells were spun down and re-inoculated into a minimal M9 medium
(kanamycin, 30 µg/ml) at half volume of LB medium. The culture was continued
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at 20 °C for one hour. A sample of the culture was take n to check its OD600 to
confirm the continuous growth of cells under lower temperature and the minimal
M9 medium. Then expression of the recombinant BP1-LRP6 was induced by
IPTG at the concentration of 1 mM for overnight at 20 °C. The cells were
harvested by centrifuge the next morning. The cell pellet was resuspended in
binding buffer (10 g/ml cells, 20 mM Tris-HCl, 500 mM NaCl, 2.5 mM imidazole, 6
M urea at pH 8.0) of His tag affinity purification system followed by sonication
while on ice. To separate the cell pellet from the supernatant, the cell pellet was
spun down. The pellet was again resuspended in the binding buffer containing 6
M urea and then sonicated on ice again. This procedure was repeated three
times to ensure complete solubilization of all bacterially expressed BP1-LRP6 in
the inclusion bodies in this buffer system. All supernatant fractions were
combined and applied on a HisBind® resin column (Novagen). The column was
extensively washed with binding buffer containing 6 M urea followed by washing
with 100-500 ml of wash buffer harboring 20-30 mM imidazole. The purified
recombinant BP1-LRP6 was eluted from the column using elution buffer with 1.0
M imidazole and 6 M urea. The eluted protein was dialyzed against 10 mM
ammonium bicarbonate to remove the unwanted salt and imidazole in the buffer .
Ultimately, the dialyzed protein solution was lyophilized to get the pure BP1LRP6 protein powder. The protein powder was weighed and was stored at -20 °C
for future experimental purposes.
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3.2.4.

Time course for QQ-protein delivery
The bacterially expressed BP1-LRP6 was modified with QQ-reagent

overnight at 4 °C with gently shaking. Modified BP1-L RP6 was centrifuged at
5000 rpm for 5 minutes to remove precipitation. Then the modified BP1-BP1LRP6was mixed with serum-free DMEM to reach a final protein concentration of
0.1 mg/ml. Eighteen dishes (35 cm2) of 80% confluent (about 0.3×106 cells) HeLa
cells were incubated with the protein delivery medium and protease inhibitor for 3
hours. Another 3 dishes of HeLa cells were incubated with QQ-reagent only (no
BP1-LRP6) for 3 hours as a negative control. Samples of HeLa cells were taken
in triplicate every 30 minutes to monitor the protein delivery efficiency. All the
samples were subjected for SDS-PAGE gel electrophoresis with or without DTT.

3.2.5.

Confocal fluorescence imaging
Zeiss Apotome microscopy system is useful for optical sectioning in

multicolor applications and for high-resolution fluorescence microscopy. We use
this system to monitor and visualize the protein delivery of fluorophore attached
BP1-LRP6.

The bacterially expressed BP1-LRP6 was first dissolved in PBS

buffer, pH 7.4 (0.5-1.0 mg/ml), overnight. The solution then was spun for 10
minutes at 12,000xg at room temperature. Seventy ul of protein solution was
taken and 1 µl of amine-reactive ArrayIt®Green540 was added at room
temperature. Incubation was carried out for 6 hours or overnight in a cold room
and then purified using a desalting spin-column at 10,000 rpm for 4 minutes to
remove free dye. The purified, fluorescence labeled protein was incubated with

121

QQ-reagent overnight without further purification. HeLa cells were seeded three
days before the experiment to reach 80% confluency. QQ-reagent modified,
fluorophore labeled BP1-LRP6 in serum-free DMEM culture medium was
incubated with Hela cells at 37 °C for 1 hour or 2 hours. The cells were very
healthy after protein delivery, displaying normal morphology (Figure 3-7). Cells
were washed with PBS extensively to remove any labeled protein from the
medium. Then the Hela cells were subjected to confocal fluorescenceimaging
using a Zeiss Axioplan2 Imaging fluorescent microscope with ApoTome imaging
at the Microscopy and Imaging Resources Laboratory at Wayne State University,
School of Medicine. Fluorescence was recorded with an AxioCam MRm camera
and AxioVision software.

3.2.6. Far-Western blot
The cell lysates on a native PAGE gel were tansferred onto a
nitrocellulose membrane at 380 mA for 2 hours. After transfer, the membrane
was incubated at room temperature with the probe---MESD, which is the private
chaperone of LRP5/6 and can specifically bind to the properly folded BP1-LRP6.
The membrane was then washed three times with 20 ml PBS for 5 minutes each
time, to remove unbound MESD. The membrane was incubated with anti-MESD
(Abnova) for 1 hour in 2% dry milk PBS, followed by incubation with HPRconjugated seconday antibody for 1 hour. At last, the membrane was detected
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using ECL (Pierce). Using this assay, properly folded BP1-LRP6 can be detected
because of the formation of the MESD/BP1-LRP6 complex.

3.2.7.

Time course for protein refolding
Protein refolding inside mammalian cells takes time, especially for BP1-

LRP6. We delivered large quantities of bacterially expressed BP1-LRP6 inside
HeLa cells. After protein delivery, we set up a three-day protein refolding time
course experiment to monitor the refolding and stability of the delivered BP1LRP6 inside HeLa cells.
BP1-LRP6 first was modified with QQ-reagent for overnight at 4 °C. Then
QQ-reagent modified BP1-LRP6 was mixed with serum-free DMEM to reach 0.1
mg/ml concentration. The protein delivery medium was incubated with 80%
confluent HeLa cells for 3 hours (the optimal protein delivery condition) at 37 °C.
Then the protein delivery medium was removed and the Hela cells were gently
washed with pre-warmed PBS buffer three times. Hela cell samples were taken
in triplicate to monitor the protein delivery. During the three-day protein refolding
time course experiment, Hela cells were incubated with fresh serum-free DMEM
and every 24 hours, HeLa cell samples were taken to monitor the protein folding
and the protein stability inside of the cells. One flask of cells was set aside, only
loading with QQ-reagent protein delivery medium (without BP1-LRP6) as a
negative control.
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3.2.8.

Detection of the refolded BP1-LRP6 by Western blot
The recombinant BP1-LRP6 was fused with His-tag. Protein purification

was performed using nickel chelating resin column. The purified refolded BP1LRP6 protein powder and the bacterially expressed BP1-LRP6 protein powder
was dissolved in PBS buffer and the concentrations of both of the proteins were
adjusted to 0.25 mg/ml, confirmed by a BCA protein assay (Pierce). Protein
samples were loaded at different volumes and analyzed by SDS-PAGE with or
without the reducing reagent, DTT. Following transferring to PVDF membrane,
successive incubation with mouse anti-His tag monoclonal antibody (Sigma) or
mouse anti-BP1-LRP6 antibody (kindly provided by Dr. Jian-Ping Jin) and
horseradish peroxidase-conjugated secondary antibodies (Amersham Life
Science) were carried out according to the routine Western blotting procedures.
The immunoreactive proteins were then detected using the ECL system.

3.2.9.

Far UV Circular Dichroism (CD) Spectroscopy
Circular dichroism (CD) spectroscopy measures differences in the

absorption of left and right circularly polarized light, which arise due to structural
asymmetry. Protein secondary structure can be determined by CD spectroscopy
in the far UV region (190-260 nm). Three common secondary structure motifs (αhelix, β-sheet, and random coil) exhibit the characteristic and distinctive CD
spectra in the far UV region. α-Helical proteins have negative bands at 222 nm
and 208 nm and a positive band at 193 nm. Proteins with well-defined antiparallel
β-pleated sheets have negative bands at 218 nm and positive bands at 195 nm,
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whereas disordered proteins have very low ellipicity above 210 nm and negative
bands near 195 nm.
CD is reported in units of ellipticity (θ
θ), usually expressed in millidegrees,
which reflects the sum of the entire molecular population in a sample solution. It
can be normalized to the molar concentration of the sample as molar ellipticity.
Circular dichroism spectroscopy is commonly used to: 1) determine if a
protein is folded; 2) characterize protein secondary structure and tertiary
structure (using near-UV CD spectrum); 3) compare the structures of a wild-type
protein with different mutants; 4) study protein stability to temperature or
chemical denaturation (GdnHCl or urea) and effects of salt, pH, organic solvents;
5) study protein folding, unfolding, denaturation or aggregation; and 6) determine
whether protein-lipid interactions alter the conformation of a protein.
In our studies, CD measurements were carried out on an Olis DSM 17 CD
spectrophotometer (Bogart, GA), with a constant 20 °C temperature capability
under computer control within ±0.2 oC. Protein concentrations were determined
by the BCA protein assay (Pierce) and absorbance at 280 nm using a
spectrophotometer, which gave a similar result of the protein concentration by
both methods. Eight hundred µl samples in 25 mM phosphate buffer at pH 7.4
were prepared. The far UV spectra were collected at 190-260 nm with a cuvette
using 250 µl sample in a 1 mm pathlength, at a protein concentration of 0.1-0.2
mg/ml. Fifteen scans between 190 and 260 nm were acquired and averaged. A
base-line scan was subtracted to produce the final average scan. The value of
molar ellipticity ([θ] x 103 deg cm2/dmole) was plotted as a function of protein
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concentration. The average α-helical, β-sheet, and other secondary structure
element content in the refolded BP1-LRP6 was calculated using DICHROWEB
server (212).

3.3.

Results

3.3.1.

Expression and purification of the recombinant BP1-LRP6 from
Escherchia coli (E. coli)
BP1-LRP6 with N-terminus His tag was expressed in E. coli. Bacterially

expressed BP1-LRP6 adopted random conformations and preferred forming
oligomers by non-native disulfide bonds. In order to break the intermolecular
disulfide bonds for monomer BP1-LRP6 protein band, all the samples in Figure
3-4 were reduced by DTT.
Figure 3-4 showed the highly efficient recombinant BP1-LRP6 expression
and the nickel chelating column purification process. The strong protein band of
37 kDa (BP1-LRP6) was shown in the IPTG-induced cell lysates while there was
no induced protein expression band in the control ( lanes 1 and 2). Large
quantities of recombinant BP1-LRP6 expressed inside E. coli caused protein
aggregation and formed inclusion bodies. We had to use 6 M urea in the
purification buffer and repeated the sonication step three times in order to extract
the recombinant BP1-LRP6. The extracted recombinant BP1-LRP6 in the buffer
was loaded onto a nickel chelating column, followed by extensive washings to
reduce non-specific proteins from binding. BP1-LRP6 was eluted out with 1 M
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Figure 3-4: A 12% reducing SDS-PAGE gel, showing the induced expression of
BP1-LRP6 in E. coli and its purification by using nickel chelating column.

Lane 1: E. coli cell lysates after IPTG induction. Lane 2: E. coli cell lysates without
IPTG induction as a negative control. Lane 3: the cell extract before loading onto the
column. Lane 4-6: the cell extract from the 1st sonication, 2nd sonication, and 3rd
sonication. Lane 7: the flow through after loading. Lane 8: the flow through of the
binding buffer wash. Lane 9: the flow through of the washing buffer wash. Lane 10:
the elution.

imidazole. The elution was dialyzed and lyophilized to obtain pure protein
powder. By using this high-yield recombinant protein expression method, we
could routinely obtain about 70 mg of pure BP1-LRP6 protein powder from 500
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ml cell culture. Pure bacterially expressed BP1-LRP6 was stored at -20 °C for
further experiments.

3.3.2.

Highly efficient protein delivery by QQ-reagent
To optimize the protein delivery condition for in vivo refolding of BP1-

LRP6, we conducted a time course of protein delivery experiment for 3 hours.
Bacterially expressed BP1-LRP6 was modified with QQ-reagent for overnight at
4 °C. The QQ-modified BP1-LRP6 was mixed with serum-fr ee DMEM to reach
the final concentration of 0.1 mg/ml. Dishes containing 80% confluent HeLa cells
were incubated with the protein delivery medium for different periods of time.
Every half hour, one dish of HeLa cells was taken out and was suspended in the
SDS-PAGE loading buffer. All the samples were analyzed by a 12% SDS-PAGE.
In order to observe the monomer band of BP1-LRP6, we ran a duplicate SDSPAGE under reducing condition.
Figure 3-5 showed the gradual appearance of a monomer BP1-LRP6
protein band (red arrow) in the Hela cell lysates samples from 0.5 hour to 3
hours. Under a reducing condition (Figure 3-5, right panel), the intensity of the
BP1-LRP6 protein band was significantly increased (red arrow). The data
demonstrated that the protein delivery of BP1-LRP6 into Hela cells was linear,
maximizing around 2 hours post delivery.
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Figure 3-5: 12% SDS-PAGEs of a time course of the QQ-delivery of the BP1-LRP6
into HeLa cells.

Lane CT: the Hela cell lysis after loaded with QQ-reagent for 3 hours as a negative
control. Lane M: protein marker. Lane 1-6: the Hela cell lysis after loaded with QQmodified BP1-LRP6 for 3 hours, 2.5 hours, 2 hours, 1.5 hours, 1 hour and 0.5 hours.
Lane 7: the bacteria expressed BP1-LRP6 powder. Lane 8: the bacteria expressed
BP1-LRP6 powder with DTT. Left panel: Without DTT. Right panel: With DTT.

Bacterially expressed BP1-LRP6 was labeled with amine-reactive
ArrayIt®Green540 and delivered into Hela cells with the QQ-reagent and imaged
using confocal fluorescence imaging (Figure 3-6). Images were taken after 1 and
2 hours after protein delivery. After 1 hour protein delivery, the fluorescence
images showed that most of BP1-LRP6 was located in the perinuclear location
inside HeLa cells, possibly in the ER for refolding (Figure 3-6, top panel).This
was confirmed by the imaging data after 2 hours of protein delievery, showing
that more BP1-LRP6 proteins were located into the perinuclear area of the HeLa
cells (Figure 3-6, bottom panel). This result confirmed our result of the time
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course of BP1-LRP6 delivery, suggesting that 2 hour protein delivery appeared to
be the optimal protein delievery time (Figure 3-5). The QQ-reagent is highly
efficient for protein delivery with most of bacterially expressed BP1-LRP6 being
delivered inside of HeLa cells, ready for refolding.

Figure 3-6: Confocal fluorescence images of the Hela cells with the delivered BP1LRP6.

BP1-LRP6 was first labeled with small molecular fluorophore (ArrayIt® Green 540
amine-reactie dye) and then modified with QQ-reagent for protein delivery.
Fluorescence images (on the left) and DIC images (on the right) were taken after 1hour and 2-hour protein delivery.
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A relatively high concentration of BP1-LRP6 was kept inside HeLa cells
during refolding. After delivering bacterially expressed BP1-LRP6 for 2 hours, we
changed the protein delivery medium for fresh serum-free DMEM for another
overnight incubation. We took samples of the HeLa cells and ran the cell lysates
sample on a SDS-PAGE. We found that BP1-LRP6 accumulated inside HeLa

Figure 3-7: A 12% SDS-PAGE analysis to semi-quantify the delivered BP1-LRP6
inside HeLa cells.

All the samples were reduced with DTT. Lane M: protein marker. Lane 1-3: 10 ul, 15
ul and 20 ul of the Hela cell lysates sample after 2 hours protein delivery and an
overnight incubation. Lane 4: the intact Hela cell lysates as negative control. Lane 5:
the modified BP1-LRP6 before loading. Lane 6: the remaining undelievered BP1LRP6 in the medium after 2 hours of protein delievery. Lane 7-10: 10 ul bacterially
expressed BP1-LRP6 powder at the concentrations of 0.25 mg/ml, 0.5 mg/ml, 0.75
mg/ml and 1 mg/ml. The concentration of the delivered BP1-LRP6 was between 0.25
mg/ml and 0.5 mg/ml.
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cells (Figure 3-7). To semi-quantify the amount of BP1-LRP6 inside of HeLa
cells, we ran the HeLa cell lysates samples and the bacterially expressed BP1LRP6 samples with known concentrations under the same reducing condition
(Figure 3-7). We found that the delivered BP1-LRP6 inside Hela cells reached
the concentration range between 0.25 mg/ml and 0.5 mg/ml (lanes 7-10, Figure
3-8). It was surprising that the protein delivery could be so efficient for BP1-LRP6
as compared to that for LBD-ApoER2 (Chapter 2).

The delivered protein

appeared stable inside HeLa cells even after overnight incubation. The
differences in delievery efficiencies could be related to the unique biochemical
properties of individual proteins (modified by QQ-reagent to differing extents,
charge, etc.).

3.3.3.

Inside of HeLa cells, the delivered BP1-LRP6 was under refolding

process, showing increasing ligand-binding ability in the Far-western blot
MESD is an ER chaperone especially binding properly folded YWTD βpropeller domains of LRP5/6 and escorting them throughout the secretary
pathway (209). We used MESD as our far-Western blot probe to specifically bind
and detect the properly folded and biologically functional BP1-LRP6 in the
samples.
Bacterially expressed BP1-LRP6 was modified by QQ-reagent and was
delivered inside of HeLa cell for 4 hours. Each hour, we collected the sample of
HeLa cells harboring delivered BP1-LRP6. All the HeLa cell samples were lysed
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Figure 3-8: Far-Western blot (MESD as probe) of BP1-LRP6.

The HeLa cells with delivered BP1-LRP6 were collected at different time point. The
samples were lysed and were subjected to far-western blot using MESD as probe.
Lane1: 1 hour. Lane 2: 2 hours. Lane 3: 3 hours. Lane 4: 4 hours. Lane 5: the
bacterial expressed BP1-LRP6 without refolding as negative control. The red arrow
shows the band site of BP1-LRP6. (Courtesy of Dr. Qianqian Li).

and, with the bacterially expressed BP1-LRP6 sample, the HeLa cell lysates
were subjected to the far-Western blot. Our result showed that the delivered
BP1-LRP6 gradually underwent conformational changes inside of HeLa cells,
showing stronger and stronger binding ability to its probe, MESD, as time went
on (as shown in Figure 3-8). This data suggested that once the bacterially
expressed BP1-LRP6 was delivered inside of HeLa cells, the refolding process
began. More bacterially expressed BP1-LRP6 was refolded and increasing
amounts of properly folded BP1-LRP6 appeared, showing its specifically binding
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to the ligand (our probe) MESD. At this point, we confirmed that the delivered
BP1-LRP6 can be refolded inside of HeLa cells. Given refolding time long
enough, more BP1-LRP6 can be properly folded showing its biological function to
bind MESD and eventually the delivered BP1-LRP6 can be totally refolded while
the persistent unfolded BP1-LRP6 can be degraded by the active mechanisms
such as ERAD or UPR.

3.3.4.

Optimization of the protein refolding protocol for BP1-LRP6
Protein refolding inside Hela cells takes time. We conducted experiments

to monitor the fate of the delivered BP1-LRP6 (Figure 3-9). Our recombinant
BP1-LRP6 does not have a signal peptide at the N-terminus, thus the refolded
BP1-LRP6 remains inside HeLa cells. We tried to prolong the in vivo refolding
time by incubating the protein delivered HeLa cells with serum-free DMEM for
three days (Figure 3-9). Every 24 hours, HeLa cell samples were taken. All the
samples were incubated with 10 mM DTT before being analyzed by 12% SDSPAGE for a monomer BP1-LRP6 protein band. Our results showed that the
amount of BP1-LRP6 inside HeLa cells was significantly decreased in the first
day of in vivo protein refolding. However, in the subsequent two days of in vivo
refolding, the amount of BP1-LRP6 inside HeLa cells was relatively stable,
showing only slight decrease. After 3 days of refolding, the HeLa cells still
appeared morphologically normal (data not shown). Since a BP1-LRP6 protein
band (red arrow) remained detectable and the protein refolding time was
maximal to 3 days. These results suggest that 2 hours of protein delievery of the
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Figure 3-9: The time course experiment on refolding BP1-LRP6 inside HeLa cells.

Lane M: protein marker. Lanes 1-3: the Hela cell lysates after incubation for 3 days, 2
days and 1 day post protein delievery. Lane 4: the Hela cell lysates of negative
control. Lane 5: the Hela cell lysis after 2 hours protein delivery. Lane 6: the modified
BP1-LRP6 before loading. Lane 7: the remaining BP1-LRP6 in the protein delivery
medium after 2-hour of protein delievery. All the samples were in the presence of 10
mM DTT.

bacterially expressed BP1-LRP6 into Hela cells by the QQ-reagent (Figure 3-5)
followed by 3 days of protein refolding inside of the cells (Figure 3-9) are likely
the optimized conditions for the refolding of BP1-LRP6 inside Hela cells.
Mammalian cells have developed mechanisms to actively remove toxic
proteins, such as unfolded or misfolded proteins. Not only the active ATP-
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consuming ER associated degradation (ERAD) and unfolded protein response
(UPR) but also the unspecific proteolytic enzymes of the lysosome can actively
degrade the toxic unfolded or misfolded proteins inside mammalian cells
(Chapter 1). Also, mammalian cells can secrete out the toxic proteins and
compact them into a less toxic amyloids stocked in the extracellular tissue.
Ultimately, accumulation of these toxic proteins in the cell cytoplasm can cause
apoptosis. It is unlikely that the unfolded BP1-LRP6 could escape away from
such a well-organized and strict control, being kept inside healthy HeLa cells. We
thought that the relatively stable stock of BP1-LRP6 inside HeLa cells after 3
days of in vivo protein folding was the potentially refolded BP1-LRP6.

3.3.5.

The high yield of refolded BP1-LRP6
Is the refolded BP1-LRP6 properly folded? How is its structure organized?

To address these questions, we need first to purify the refolded BP1-LRP6 from
the HeLa cells after three-day in vivo protein folding (Figure 3-10). In order to
keep the native conformation of the refolded BP1-LRP6 as it was inside Hela
cells, no denaturing reagent was used in the buffers of nickel chelating column
purification. Due to the protein-protein interactions inside HeLa cells, non-specific
proteins could be co-purified (data not shown). To solve the problem, we
modified the purification protocol by increasing NaCl concentration up to 1 M in
the buffers. This modification greatly improved the quality of the eluted refolded
BP1-LRP6. The column was extensively washed and the refolded LRP6 was
eluted by an imidazole concentration gradient (lanes 7-9, Figure 3-10).
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To identify the purified refolded BP1-LRP6, Western blot against anti-His
tag antibody and anti-LRP6 were applied to the same quantity of the purified
refolded BP1-LRP6 and the bacterially expressed one (Figure 3-11). Purified
refolded BP1-LRP6 showed strong positive signals detected by both anti-His tag
antibodies and anti-LRP6 antibodies, identifying the re-purified protein as the
refolded BP1-LRP6 (Figure 3-11). In the anti-His tag Western blot, both the
bacterially expressed and the refolded protein powders showed positive signals
of BP1-LRP6 at the monomer position. Compared with the bacterially expressed
BP1-LRP6, our in vivo protein refolding method had significantly enriched
monomeric BP1-LRP6 in the sample.

Figure 3-10: Re-purification of refolded BP1-LRP6 from Hela cells.
Lane 1: the bacteria expressed BP1-LRP6 powder. Lane 2: the Hela cell extract
before loading onto His•Bind column. Lane 3: the flow through after loading. Lane 4:
the flow through of binding buffer washing. Lane 5-6: the flow through of washing
buffer wash (20 mM and 70 mM imidazole washing). Lane 7-9: the elution at 100mM,
250mM and 1M imidazole concentrations. All the samples were treated with 10 mM
DTT before analyzed by 12% SDS-PAGE.
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Figure 3-11: Anti-His tag (Left panel) and anti-LRP6 (right panel) western blotting
to identify purified refolded BP1-LRP6.

The left panel: all the protein samples were at 50 ng/µl and without DTT. Lane 1: 10
ul (500 ng) bacteria expressed BP1-LRP6. Lane 2: 10 ul (500 ng) purified refolded
BP1-LRP6. The right panel: all the protein powder sample were at the concentration
of 50 ng/ul. Lane 1-3: 4 ul, 8 ul, and 12 ul (200, 400, and 600 ng, respectively)
purified refolded BP1-LRP6. Lane 4-6: 4 ul, 8 ul and 12 ul bacterial expressed BP1LRP6 at the same concentrations.

The crystal structure of the homologue of BP1-LRP6, the LDL receptor BP
domain, had been solved (PDB file # 1IJQ) (130). In this structure, we noticed
that the six cysteine residues in EGF-like domain formed three intramolecular
disulfide bonds. Only the properly folded BP1-LRP6 should have structure
similarities to the LDL receptor BP domain; its cysteine residues should also only
form intra-domain disulfide bonds. If folded properly, the oligomeric species
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(intermolecular bonds) should be greatly reduced while the monomeric band
(intramolecular bonded form) (37 kDa) should be greatly enriched.

This is

exactly what was observed (lanes 1 and 2, the left panel of Figure 3-11). This
finding suggests that this in vivo protein refolding technique enables efficient
refolding of BP1-LRP6. Previous published data (211) supports this conclusion,
showing that the molecular chaperone MESD was co-overexpressed with BP1LRP6 to facilitate its folding. MESD dramatically enhanced the folding of BP1LRP6, and the properly folded BP1-LRP6 was secreted into the medium. Only
one monomer band of the secreted BP1-LRP6 was shown in their Western blot.
Therefore, the monomer BP1-LRP6 represents the potential properly folded BP1LRP6. Our purified refolded BP1-LRP6 had large percentage of the properly
folded BP1-LRP6.
The in vivo protein refolding method was optimized specifically for BP1LRP6. The bacterially expressed BP1-LRP6 was modified by the QQ-reagent at
0.1 mg/ml (final concentration). Protein delivery was conducted for 2 hours and
protein was extensively refolded inside of HeLa cells for 3 days. After 3 days of
refolding, the potentially properly refolded BP1-LRP6 was purified by HisBind
(Nickel chelating) column chromatography. A high yield of the refolded BP1LRP6 was achieved through this in vivo refolding process. The yields of the
refolded BP1-LRP6 from two independent purification schemes are shown in
Table 3-1. We routinely obtained a yield of around 60%.
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Table 3-1: The final yield of the purified refolded BP1-LRP6 using in vivo protein
refolding technique.

3.3.6. Well-defined secondary structure shown in the far-UV CD spectrum
of refolded BP1-LRP6
Far-UV circular dichroism (CD) spectroscopy is an excellent tool for rapid
determination of the secondary structure and folding properties of proteins. CD
spectra of the purified refolded BP1-LRP6 and the bacterially expressed BP1LRP6 were recorded in 50 mM sodium phosphate buffer at pH 7.4. The results
showed very different spectra for these two samples (Figure 3-12). While the
spectrum of the bacterially expressed BP1-LRP6 was more characteristic of a
random coil, the spectrum of the purified refolded BP1-LRP6 showed a positive
CD signal at 193 nm and negative CD signal near 218 nm, suggesting a
predominantly defined β-sheet structure. This result is consistent with the crystal
structure of the homologue of BP1-LRP6--- the LDL receptor BP domain, in
which six YWTD repeats together fold into a six-bladed β-propeller and each
blade is consisted of four-stranded β-sheets. Also, in the CD spectrum of the
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refolded BP1-LRP6, the negative CD peaks centered near 208 nm and 222 nm
suggest that the refolded BP1-LRP6 also contains some α- helical structure.
To further quantify the result, we sent the CD data of the refolded BP1LRP6 to the DICHROWEB server (212). DICHROWEB is a user-friendly interface
to analyze CD spectra. As the spectra of proteins that have been characterized
by x-ray crystallography are standards, DICHROWEB compared the spectra of
the refolded BP1-LRP6 with the standards using programs such as CONTINLL,
VARSLC, K2d, CDSSTR, and SELCON3 (212), assuming that the spectrum of a

Figure 3-12: Far-UV circular dichroism (CD) spectrum of the bacterially expressed
BP1-LRP6 and the purified refolded BP1-LRP6.

The right panel showed the CD samples on 12% SDS-PAGE. Lane 1 is the refolded
BP1-LRP6 protein sample. Lane 2 is the bacterially expressed BP1-LRP6 protein
sample. Both samples had reacted with 10 mM DTT.

141

protein can be represented by a linear combination of the spectra of its
secondary structural elements, plus a noise term, which includes the contribution
of aromatic chromophores and prosthetic groups (213). The calculated
secondary structure element content of the refolded BP1-LRP6 was shown as
Table 3-2. Compared with its homologue---the LDL receptor BP domain, the
refolded BP1-LRP6 had almost the same high content of β- sheet and small
percent of α- helices. The percentage numbers of the secondary element are so
close that it strongly supports the idea that the refolded BP1-LRP6 adopts a
similar conformation as the LDL receptor BP domain, further confirming that our
refolded BP1-LRP6 was properly folded and adopted a defined and a potentially
native conformation.
Table 3-2: Comparison of the secondary structure content of the refolded BP1LRP6 (using DICHROWEB web server) with that of the BP domain of LDLR (130,
212).
Secondary Structure

3.4.

Alpha-helix (%)

Beta-sheet (%)

Loop (%)

The refolded BP1-LRP6

2.6

41.0

56.4

LDL receptor YWTD-EGF

2.0

46.0

52.0

Discussion
LRP5 and LRP6 are unique members of LDL receptor family. Instead of

having clusters of ligand binding repeats in the extracellular domain to exert

142

ligand-binding function, the YWTD β-propeller/EGF (BP) modules occupies large
part of the extracellular domain and plays an important role in ligand binding.
Especially in Wnt signal transduction, LRP5/6 acts as co-receptor of the
canonical Wnt/β-catenin pathway. Malfunctions of LRP5 can cause disorder in
bone metabolism (152). LRP6 mutations associate with coronary artery disease,
Alzheimer’s disease, and cancer (192). Structural studies on LRP5/6 are very
important to understand the mechanisms of the above diseases.
BP1-LRP6 is a 328 amino acids (37 kDa) fragment, including six YWTD βpropeller motifs and one EGF-like repeat. No previous structural study on LRP6
has been reported. But, as the homologue of BP1-LRP6, the x-ray
crystallography structure of LDL receptor YWTD β-propeller/EGF (BP) domain
has shown that the six YWTD repeats of LDL receptor was folded into a sixbladed β-propeller domain. Each blade consisted of four-stranded β-sheets.
EGF-like domain tightly packs against the second and third blades of the
propeller.
Refolding the bacterially expressed BP1-LRP6 in vitro is challenging. BP1LRP6 is a 37 kDa protein with multiple motifs. During in vitro refolding, the
exposed hydrophobic residues in the refolding intermediates may cause
irreversible aggregation by hydrophobic interactions or non-native hydrogen
bonding. Also, without help of molecular chaperones and folding enzymes,
especially RAP and MESD, it is very difficult to form native intra-repeat disulfide
bonds in the EGF-like repeat of BP1-LRP6 for a proper folding.
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Instead of using traditional in vitro protein refolding methods, we used our
novel in vivo protein refolding technique to refold bacterially expressed BP1LRP6. With optimized conditions, QQ-reagent efficiently delivered large quantity
of bacterially expressed BP1-LRP6 inside HeLa cells within two hours (Figure 3-5
to 3-7). Protein refolding was extensively processed inside HeLa cells for three
days (Figure 3-9). During these three days, the bacterially expressed BP1-LRP6
underwent refolding facilitated by the ER molecular chaperones and folding
enzymes. Persistent unfolded or misfolded BP1-LRP6 could be actively
degraded by the ERAD or UPR mechanism in the ER.
During BP1-LRP6 folding, MESD may play a key role to escort the
properly folded BP1-LRP6 travel from the ER to Golgi. We delivered a large
quantity of BP1-LRP6 inside Hela cells for refolding (Table 3-1). The quantity
may be above the threshold of endogenous MESD, causing the refolded BP1LRP6 to be retained inside of the Hela cells. Also, the refolded BP1-LRP6 was
lacking a signal peptide, which may cause the difference in localization
(intracellular versus secreted) of the refolded BP1-LRP6.
We used a nickel chelating column to purify the refolded BP1-LRP6 from
HeLa cell lysates (Figure 3-10). We found our purified and potentially refolded
BP1-LRP6 was greatly enriched for the monomeric form (Figure 3-11). The
refolding efficiency and the final yield for this cysteine-rich, large-sized protein
were so high that nearly 60% percent of the delivered BP1-LRP6 was refolded
and re-purified. To futher purify our refolded BP1- LRP6, the protein could be
applied to a size exclusion chromatography to separate the monomeric species
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from the higher molecular weight oligmeric ones. A functional assay was
performed to prove that the BP1-LRP6 obtained by our novel in vivo protein
refolding technique was properly refolded and biologically functional (Figure 3-8).
This provided more evidence that the refolded BP1-LRP6 was in a native
conformation.
The secondary structure and folding properties of the refolded BP1-LRP6
was studied by far-UV circular dichroism (CD). Our CD data showed that the
refolded BP1-LRP6 adopted a β-sheet rich conformation while the spectrum of
the bacterially expressed BP1-LRP6 was more characterized as random coil
(Figure 3-12). The DICHROWEB server further analyzed and quantitated the CD
data (Table 3-2). The analysis showed that the refolded BP1-LRP6 and its
homologue, the LDL receptor BP domain shared almost the same percentage of
α-helix and β-sheet in their structure, suggesting that our refolded BP1-LRP6
adopted similar defined conformation as its homologue, the LDL receptor BP
domain. Our in vivo protein refolding technique is unique because it gives a more
physiological relevant in-cell environment for protein refolding. In this
environment, not only the refolding is assisted by molecular chaperones and
folding enzymes in the ER, but also the folding quality is strictly monitored by a
complex quality control system inside the mammalian cells. Compared with
traditional in vitro protein refolding methods, our method is much more efficient in
large protein refolding, which has been demonstrated in the refolding of LBDapoER2 (Chapter 2). However, endogenous ER chaperones and folding
enzymes have their threshold for protein folding. This may cause the retention of
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the refolded protein inside of the mammalian cells or partially refolding of the
delivered protein. We confronted these problems when we challenged our in vivo
protein refolding technique with cysteine-rich, large-size protein, BP1-LRP6. We
hope we can overcome these problems by further optimizing our in vivo protein
refolding technique or by engineering mammalian cells that can sustain large
quantity protein refolding.
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CHAPTER IV
Conclusion and future directions
4.1. Conclusion
Studies of in vitro protein refolding allow us to understand fundamental
aspects of the folding mechanisms without the complications of the biological
environment. From Anfinsen’s RNase renaturation experiment, it has been long
accepted that all the driving forces and guiding information of protein folding are
embedded in the primary amino acid sequence of a protein and no external
template is required. Under physiological conditions, the native state protein
adopts the most thermodynamically stable conformation. In vitro refolding
process is a good model for defining the types of intramolecular interaction that
drive polypeptide folding and understanding the mechanisms of protein folding.
However, in vitro refolding cannot accurately reflect the folding process of
nascent proteins inside of cells due to the differences between protein folding in
the intracellular environment and those in the test tube: 1) the intracellular
environment is a highly crowded macromolecular environment; 2) folding inside
of the cell is facilitated by molecular chaperones and folding enzymes and must
be accomplished in the context of the synthesis of polypeptide chains on
ribosomes; 3) cells are an intrinsically dynamic system. Protein folding
experiments in vitro may not mimic the dynamics states in vivo. Ultimately,
protein folding must be studied in a cellular context. It is necessary to develop
new techniques using new in vivo systems to integrate the best aspects of both
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the high-level bacterial expression system and the efficient cellular folding
machinery of mammalian cells.
Our novel in vivo protein refolding technique uniquely integrates these two
aspects. This technique first expresses recombinant proteins in E. coli with a very
high-yield and then deliver the bacterially expressed pure protein directly into the
ER of HeLa cells, using the QQ- protein delivery system, to properly refold the
protein by the comprehensive protein folding machinery inside of mammalian
cells. We drive the proteins into the inclusion bodies for the purpose of high yield
and high purity. We then purify the recombinant proteins under denatured
conditions since the bacterially expressed proteins will be refolded in the HeLa
cells. The key step of this in vivo protein refolding technique is the QQ-protein
delivery system that allows specific delivery of the bacterially expressed proteins
into the ER for efficient refolding. This novel in vivo protein refolding technique
offers a unique tool for protein folding study as well as for broader applications,
such as therapeutical protein productions.
This thesis also presents the applications and optimizations of our novel in
vivo protein refolding technique on two challenging proteins: LBD-apoER2 and
BP1-LRP6. ApoER2 is an important LDL receptor super family member involved
in ApoE metabolism in brain and the onset of Alzheimer’s disease. The LBDapoER2 contains 7 ligand binding repeats. Each repeat contains 6 cysteines
forming 3 intra-repeat disulfide bonds, plus one Ca2+-binding site. Bacterially
expressed LBD-apoER2 formed non-native disulfide bonds, causing multiple
conformations and aggregation. LRP6 is the co-receptor of Wnt signalling
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pathway, involved in cell proliferation, differentiation and mobility. The homologue
of BP1-LRP6, BP domain of LDL receptor, adopts a β-sheet rich conformation. In
BP domain of LDL receptor, the YWTD β-propeller module is composed of six βstrand blades and the C-terminal EGF-like module is stabilized by three intradomain disulfide bonds. Bacterially expressed BP1-LRP6 was misfolded and
formed large amounts of oligomers.
By using our in vivo protein refolding technique, we efficiently delivered
the misfolded proteins into the ER of HeLa cells. Under the physiological
environment of ER and with the help of molecular chaperones and folding
enzymes, the misfolded proteins were efficiently refolded into their native
conformations. The refolded LBD-apoER2 displayed RAP binding function,
implying its proper conformation. The refolded BP1-LRP6 also showed biological
function of MESD binding ability, indicating the appearance of native
conformation after refolding. Far-UV circular dichroism spectra of the refolded
BP1-LRP6 indicated a β-sheet rich structure. The data analysis of the far-UV
circular dichroism spectra provided indirect evidence that the refolded BP1-LRP6
adopted a remarkably similar secondary structure as its homologue --- BP
domain of LDL receptor. Based on our results, we concluded that the application
of our novel in vivo protein refolding method gave high yields of properly folded
LBD-apoER2 and BP1-LRP6.
This novel in vivo protein refolding technique not only provides an efficient
tool to obtain large quantities of properly folded recombinant proteins with stable
isotopes for structural apporaches such as NMR spectroscopy, but also opens
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interesting new perspectives for producing biological active polypeptides and
proteins with therapeutic value on a large-scale. Moreover, this technique bridges
the existing technical gap between in vitro protein folding and folding in living
cells and can be used to gain a fundamental understanding of dynamic
intracellular folding mechanisms in the living mammalian cells by studying the
folding of the radioactive amino acid labelled recombinant proteins inside of
mammalian cells. Or, as the fluorescence based techniques (such as fluorescent
resonance energy transfer, FRET) develop, we can expect to study
conformational changes of proteins in the living cell.

4.2. Future Directions
We have successfully refolded LBD-apoER2 and BP1-LRP6 into their
native comformations with biologically functions by applying the in vivo protein
refolding technique. The logical next step is to investigate the biochemical and
structural characters of these properly folded proteins under physiologically
relevant circumstances. One of strengthes of our in vivo protein refolding is that
we can efficiently refold isotope-labelled bacterially expressed proteins into their
native conformations. With isotope labelling, the refolded LBD-apoER2 and BP1LRP6 can be dissolved in physiologically relavent buffers, ready for NMR
structural studies. BP domains of LRP6 is involved in Wnt signalling pathway and
LBD-apoER2 may be involved in the onset of Alzheimer disease. They are
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potentially important drug targets. Detailed structure information on these two
proteins can be very helpful for drug design.
The folding of the cysteine-rich ligand binding repeats of LBD-apoER2
relies on a special ER/Golgi resident molecular chaperone RAP (138). RAP
escorts the ligand binding domain and inhibits pre-mature ligand binding through
the secretary pathway. RAP exerts high binding affinity to the ligand binding
domain of the LDLR family (KD~ 1-10 nM) in the ER (125, 138, 139). But under
the acidic environment of Golgi, RAP is released fom the binding complex by
lowering the binding affinity to ligand binding repeats. The RAP releasing
mechanism in Golgi is still not clear. Acoording to the x-ray crystal structure of
RAP-D3 and LDLR-LA3-4, A low-pH induced unfolding model was proposed
(214). In this model, the histidine residues which are buried in the hydrophobic
interior of

the RAP-D3 helical bundle are protonated under the low pH

environment of Golgi and, in sequence, trigger unfolding of the helical bundle and
dissociation of RAP-D3/LDLR-LA3-4 complex. However, Gettins’ group found
that domain D1 of RAP also bound LA repeats of LRP with very high affinity
(215). In their low-pH induced YWTD displacing model, the flanking YWTD
“propeller” domains competitively bind to RAP at the two binding sites in RAP-D1
and RAP-D3 under the low pH environment of Golgi. Thus, RAP is displaced by
YWTD domains, releasing from LA repeats. The debating of these two models
diverges at different study objects. The low-pH induced YWTD displacing model
claimed for the acuteness by applying the intact RAP and three ligand binding
repeats of LRP instead of RAP-D3 and two ligand binding repeats only of LDLR.
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To clear the debating, we can conduct isothermal titration calorimetry (ITC)
experiments on the protein-protein interactions between the intact RAP (available
in our lab) and our refolded LBD-apoER2 which contains the whole ligand
binding domain (seven ligand binding repeats) at different pH environments. This
research will offer direct evidences to elucidate the RAP releasing mechnism in
Golgi.
Protein chaperones are involved in the protein folding process inside of
cells. For example, Bip, the abundant general ER chaperone, usually is the first
chaperone binding to the nascent peptide chain to facilitate translocation of the
nascent peptide chain into the ER lumen. PDI is one of the most important ER
chaperones facilitating the native disulfide bond formation (28). RAP is the
specific folding chaperone for the ligand-binding domain of LDLR superfamily
members (125). MESD is the private chaperone for LRP5/6 BP domain folding
(139). In our research, the folding threshold of endogenuous molecular
chaperones and folding enzymes was the main factor that limits the in vivo
protein refolding efficiency. Our QQ- protein delivery system is powerful. We can
co-deliver important molecular chaperones or folding enzymes inside of cells with
the proteins of interest to overcome the folding threshold problem and to further
increase the refolding efficiency of the in vivo protein refolding technique.
On the other hand, the host mammalian cells could also be engineered for
the purpose of improving in vivo protein refolding efficiency. Reports have
provided examples of how the growth, survival, and productivity of the host cell
can be improved through use of these genetic engineering techniques. Proto-
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oncogenes, cell cycle control genes (cyclins), growth factor genes (e.g., insulinlike growth factor), and anti-apoptotic genes have been inserted into cell lines for
the generation of superior recombinant protein production hosts (216).
Improvements of in vivo protein refolding and post-translational modification can
also be achieved by genetic engineering method. Stable cell lines can be
generated by integrating key genes of molecular chaperones or folding enzymes
into the host cell genome. These engineered host cell lines stably overexpress
these important molecular chaperones or folding enzymes and they can be used
as the refolding host cell lines to enhance the refolding ability. Thus, the protein
refolding efficiency by using these engineered host cells may be significantly
improved.
The establishment of a basis for understanding the determinants of protein
folding has the potential to transform our understanding of many of the most
perplexing issues surrounding protein folding diseases, and perhaps most
importantly, the true nature of misfolded pathogenic protein species. Our in vivo
protein refolding technique has opened the field for in vivo analysis of protein
folding diseases, which has previously only been possible in vitro. We believe
this approach may become a fundamentally important technique that could aid in
understanding the protein folding and the complex chaperone networks inside of
cells and its physiological relevance could, ultimately, be of clinical benefit.
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R.J., Back, S.H., Song, B., Han, J., and Hassie, J. (2010) The unfolded protein
responses is required to maintain the integrity of the endoplasmic reticulum, prevent
oxidative stress and preserve differentiation in beta-cells. Diabetes Obes Metab 12
Suppl 2, 99-107.
With permission from CCC
Rightslink Printable License 6/12/11 2:34 PM

157

JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jun 12, 2011
This is a License Agreement between Yuefei Huang ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and
Sons, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 2686630362972
License date Jun 12, 2011
Licensed content publisher John Wiley and Sons
Licensed content publication Diabetes, Obesity and Metabolism
Licensed content title The unfolded protein response is required to maintain the integrity
of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in
beta‐cells
Licensed content author R. J. Kaufman,S. H. Back,B. Song,J. Han,J. Hassler
Licensed content date Oct 1, 2010
Start page 99
End page 107
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Electronic
Portion Figure/table
Number of figures/tables 1
Number of extracts Original Wiley figure/table number(s) Figure 2
Will you be translating? No
Order reference number
Total 0.00 USD

158

Figure 1-4: The energy landscape depiction of protein folding. Adapted from
Brooks, C.L., 3rd, Onuchic, J.N., and Wales, D.J. (2001) Statistical thermodynamics:
Taking a walk on a landscape. Science 293, 612-613.
With permission from CCC
Rightslink Printable License 6/12/11 3:19 PM
THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE LICENSE
TERMS AND CONDITIONS
Jun 12, 2011
This is a License Agreement between Yuefei Huang ("You") and The American
Association for the Advancement of Science ("The American Association for the
Advancement of Science") provided by Copyright Clearance Center ("CCC"). The
license consists of your order details, the terms and conditions provided by The
American Association for the Advancement of Science, and the payment terms and
conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 2686650058529
License date Jun 12, 2011
Licensed content publisher The American Association for the Advancement of Science
Licensed content publication Science
Licensed content title Taking a Walk on a Landscape
Licensed content author Charles L. Brooks III, José N. Onuchic, David J. Wales
Licensed content date Jul 27, 2001
Volume number 293
Issue number 5530
Type of Use Thesis / Dissertation
Requestor type Other Individual
Format Electronic
Portion Text Excerpt
Number of pages requested 1
Order reference number
Title of your thesis /dissertation a novel in vivo protein refolding technique

159

Expected completion date Aug 2011
Estimated size(pages) 200
Total 0.00 USD
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Figure 2-3: The crystal structure of LDL receptor residue 1-699 at pH 5.3. Adapted
from Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M.S., Golstein, J.L.,
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Figure 2-5: ER export and retrieval cycle of RAP- Role in LRP secretion. Adapted
from Herz, J. (2006) The switch on the RAPper’s necklace. Mol Cell 23, 451-455.
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Figure 3-1: A schematic representation of the Wnt signal transduction cascade.
Adapted from Habas, R., and David, L.B. (2005) Dishevelled and Wnt signaling: is the
nucleus the final frontier? J. Biol 4,2.
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Figure 3-3: Ribbon representation of the YWTD domain and adjacent C-terminal
EGF-like module (E3) of the LDL receptor, colored to point out the six YWTD
repeats of the six-bladed propeller. Adapted from Jeon,H., Meng, W., Takagi, J., Eck,
M.J., Springer, T.A., and Blacklow, S.C. (2001) Implications for familial
hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair.
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Proteins perform their functions in their native folded states and misfolding
of proteins may cause severe diseases, including Alzheimer’s disease,
Parkinson’s disease, prion disease and diabetes. Understanding protein folding
is important for us to engineer proteins to treat these diseases. For protein
therapeutics, large quantities of properly folded and functional proteins are
required. The current technology produces recombinant proteins using either
eukaryotic or prokaryotic expression system, both of them have major problems
that prevent production of large quantities of properly folded and functional
human proteins for protein therapeutics.
Although the eukaryotic cells have comprehensive folding machinery that
contains chaperones and folding enzymes and a complex quality control (QC)
system to ensure that only properly folded proteins will be generated to perform
their functions, either intracellular or extracellular, the protein yield is usually very
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low. Protein production using this system is usually costly. In contrast,
prokaryotic cells can be used to produce large quantities of recombinant human
proteins at a low cost. However, the produced human proteins using prokaryotic
cells usually misfold and are not functional due to the much simpler protein
folding machinery and QC system of these prokaryotic cells. To solve this
problem, the in vitro protein refolding technique has been developed that either
mimics the intracellular redox conditions to promote protein folding at a diluted
concentration or uses column chromatography to refold the misfolded
recombinant proteins. Although this in vitro protein folding technique has some
success for small proteins with simple folds, the refolding efficiency is generally
very low. For large proteins of complex folds of multiple domains, this in vitro
protein refolding technique is usually not working.
To solve these challenges, our lab recently developed an in vivo protein
refolding technique that uses the intracellular folding machinery and QC system
of the Endoplasmic reticulum (ER) of mammalian cells to refold the misfolded
recombinant proteins produced using bacterial expression system. This novel
technique uses the QQ-protein delivery technology developed in our lab to
directly deliver bacterially expressed proteins into the ER for refolding. We
showed that the intracellular folding machinery of mammalian cells had a large
capacity to properly refold large quantities of misfolded bacterially expressed
proteins and the QC system of the mammalian cells ensured that only properly
folded proteins followed the normal intracellular trafficking pathway as their
endogenous counterparts. Since the refolded proteins contain an affinity tag, we
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can purify the properly refolded proteins. This in vivo refolded technique takes
the advantage of the high yield prokaryotic expression system and the
comprehensive protein folding machinery/QC system of mammalian cells to
efficiently produce large quantities of properly folded and biologically functional
proteins.
I optimized this in vivo protein refolding technique for the betapropeller/EGF domain I of LDL receptor-related protein 6 (BP1-LRP6) and the
ligand-binding domain of apolipoprotein E receptor 2 (LBD-ApoER2). These two
proteins contain a large number of cysteines that form intracellular disulfide
bonds. The folding of these two proteins is very challenging. I performed
optimizations of experimental conditions that allow me to produce large quantities
of properly folded and functional BP1-LRP6 and LBD-apoER2. The yield of
refolding is about 20-60%, depending on different proteins, allowing me to
produce milligram quantity of properly refolded and functional BP1-LRP6 and
LBD-apoER2. The Far-UV Circular Dichroism (CD) Spectrum of refolded BP1LRP6 showed a high percentage of beta-sheet which is consistent with the x-ray
crystal structure of the beta-propeller/EGF domain of low-density lipoprotein
receptor (LDLR). Refolded LBD-apoER2 showed the biological function of active
binding the chaperone receptor-associated protein (RAP) in the ligand-blotting
assay. My results suggested that, as a new tool, this protein refolding technique
can be used to produce large quantities of properly folded and biologically
functional proteins for many applications including protein therapeutics to treat
human disease, structural biology and protein folding studies.
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